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ABSTRACT 
 
This dissertation is a culmination of several projects that each explore how early-
life diet or drug can impact later-life health outcomes.  The first chapter is an introduction 
to provide important context or supplementary information (in addition to the 
introduction in each chapter).   
Chapter 2 is a collaborative project testing the adipose-tissue specific effect of 
three Interventions Testing Program (ITP) drugs that extend median lifespan in mice: 
acarbose (ACA), 17α-estradiol (17aE2), and rapamycin (Rapa).  We hypothesized these 
three ITP drugs may extend life through the reduction of adipose tissue inflammation.  
We found ACA and 17aE2 do not alter adipose tissue inflammation.  Rapa-treated HET3 
mice have increased M1 adipose tissue macrophages.  We conclude that Rapa’s lifespan 
extension benefits occur in the context of exacerbated adipose tissue inflammation.   
Chapter 3 documents the spontaneous outbreak of C. difficile infection (CDI) in 
our mouse colony. During this outbreak, methyl-donor supplementation (MS) diet F1 
mice had higher mortality than control diet F1 mice.  We hypothesized the MS diet alters 
F1 gut microbiota in a way that increases CDI susceptibility.  In Chapter 4, we tested if 
MS diet affects gut microbiota, and if so, whether these changes affect colonization 
resistance. We found the MS diet F1 mice gut microbiota is enriched with Lactobacillus, 
Porphyromonadaceae, and Bacteroides and decreased abundance of certain types of 
Bacteroides, Akkermansia, and Alistipes.  We show that F0 diet can lead to an altered F1 
gut microbiota. Interestingly, the altered gut microbiota does not compromise F1 
colonization resistance to the 16N203 C. difficile spore dosage we tested.      
The MS diet is modeled after the diet, epigenetic, and obesity link established in 
the agouti viable yellow (Avy) mice.  In Chapter 5, we hypothesized the MS diet can 
protect C57BL/6J F1 mice from diet-induced obesity in adult life through reduction of 
adipose tissue inflammation.  We found that the MS diet generally does not alter obesity 
susceptibility nor metabolic inflammation outcomes in C57BL/6J F1 mice.   
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Chapter 1 – Introduction 
 
Portions of this chapter have been published:   
 
Theresa Mau and Raymond Yung.  Adipose tissue inflammation in aging. (2017) 
Experimental Gerontology. Review. DOI: 10.1016/j.exger.2017.10.014. PubMed PMID: 
29054535. 
 
The introduction contains the background information partitioned into 5 
subsections.  These 5 subsections will first cover some literature that discusses the 
relationship between diet and later-life disease using the developmental origins of health 
and disease (DOHaD) concept.  Following this, I will describe the methyl-donor 
supplementation (MS) diet used in Chapters 3-5, and I highlight a few studies that have 
tested later-life disease outcomes using a similar peri-/pre-natal methyl-donor diet.  Next, 
I discuss adipose tissue inflammation in the context of diet-induced obesity (DIO) in the 
young (metaflammation) and age-associated obesity in the old (inflammaging).  These 
details and concepts are useful for understanding the adipose tissue biology for Chapters 
2 and 5.  In the last subsection, I briefly review the role of fat mass in longevity and 
provide some history of the National Institute of Aging’s Intervention Testing Program 
(ITP) and the HET3 mice which are 4-strain crossed mice (first generation offspring of 
CByB6F1/J and C3D2F1/J parents) we use in Chapter 2. 
 
Developmental Origins of Adult Health and Disease 
Early-life nutritional programming influences offspring disease susceptibility 
across generations1,2, in part through epigenetic mechanisms including DNA methylation, 
histone modifications, and the gut microbiome.  Fetal programming in utero is affected 
by environmental factors, including early-life exposure and adaptation to maternal 
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nourishment levels3–5.  The Hales and Barker ‘thrifty phenotype hypothesis’ is often used 
to explain the potential mismatch of in utero adaptations to ex utero conditions, forming 
the developmental origin of adult metabolic disease 6,7.  This notion is now expanded to 
broadly include any disease that may result similarly from ‘soft inheritance’ of epigenetic 
marks that affect adult life disease in offspring.   
 
A well-known example of diet and later-life disease in humans was the 
association found between 1st trimester in utero exposure to the Dutch famine of 1944-
1945 and low birthweights3, and this association was also then linked to another 
important observation:  a majority of these fetuses in their adult life succumbed to 
cardiovascular disease.  This was not the first case where the correlation between low 
birthweights and heart disease was noted, an earlier study similarly reported this 
connection in the Hertfordshire records8 of Britain in the 1900s.  These epidemiological 
studies form the basis to the developmental origins of health and disease, and in 
particular, it supports the existence of a relationship between maternal nutrition and fetus 
later-life disease risk5.   
 
It is believed that the fetus makes adaptations based on environmental stresses, 
including nutrition levels, to better cope with anticipated ex utero environment.  
However, if the fetus is born into an environment where there is significantly higher 
nutrition availability, then this ‘mismatch’ adaptation can translate into poorer metabolic 
health9–12, especially if they experience “catch-up” growth12.  These fetal intra-womb 
‘decisions and adaptations’ are believed to be penned with epigenetic marks, enabling 
developmental plasticity.   
 
Prenatal Nutrition and Epigenetics 
During development, the integrity of DNA methylation is indispensable for 
temporal silencing of specific genes to differentiate tissues at the correct stages of 
growth.   Maternal intake of macronutrients and micronutrients play a crucial role in the 
infant’s development, because the availability of resources (metabolites) for DNA 
methylation can affect this process13.  DNA methylation and histone modifications were 
3 
 
considered to the two major epigenetic mechanisms.  However, within the last decade, 
DNA methylation, histone modifications, and non-coding RNA (microRNA) regulation 
are all surfacing as major and highly interconnected epigenetic mechanisms14.   
 
A group of enzymes, DNA methyltransferases (DNMTs), catalyze the addition of 
the methyl group to the DNA.  The DNMT family includes DNMT1, DNMT3a, 
DNMT3b, and DNMT3l.  During DNA replication, hemimethylated DNA are important 
intermediates for DNA methylation to be maintained in cell lineages, but during 
replication and embryogenesis, de novo methylation of DNA also occurs15,16.  DMNTs 
facilitate the addition of a methyl group at the C5 position of cytosine residues on CpG 
(cytosine-phosphate-guanine) islands.  S-adenosylmethionine (SAM) is as an 
intermediate methionine metabolism product that acts as a methyl-donor for methylation 
processes17.   
 
Methyl-donor supplementation (MS) diets have been used in studies as a prenatal 
diet and include folate, choline, betaine, and vitamin B12.  The MS diet leads to 
hypermethylation of Avy and AxinFu alleles in mice.  This results in fewer F1 Avy mice 
born with pseudoagouti (brown) coat color which is associated to decreased obesity18, 
and it also leads to reduced severity of tail-kinking in AxinFu mice19.  Choline and betaine 
(metabolite formed from choline) also influence DNA and histone methylation status.  
Betaine donates a labile methyl group to homocysteine to form methionine and 
eventually lead to SAM synthesis which is the methylating agent and required cofactor 
for DMNTs20.   
 
Methyl-donor diet intervention and later-life diseases (Ch. 3-5) 
Viable Agouti mouse model of obesity and epigenetics 
A clear demonstration of epigenetic inheritance of metabolic disease is the viable 
agouti Avy mouse model of obesity18,21.  The agouti gene encodes a paracrine signaling 
molecule that produces either black eumelanin (a) or yellow phaeomelanin (A) which 
influences coat color.  An endogenous retrovirus-like gene that is known as the 
intracisternal A particle (IAP) retrotransposon insertion leads to ectopic expression of the 
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agouti gene, and this leads to the agouti coat color and proneness to developing obesity 
and tumors, shortening the lifespan of F1 mice.  When a methyl-donor supplementation 
(MS) diet is prescribed to the dams, the F1 mice were protected by methylation on the 
agouti IAP gene promoter site22, and degree of methylation on the promoter (up to 9) 
shifts F1 mice towards corresponding pseudoagouti coat colors23.  These protective marks 
suppress ectopic expression of the agouti gene and is associated with decreased obesity18 
and tumorigenesis in F1 mice24, leading to increased lifespan.  The observations from the 
viable agouti mouse model lend insight into the relationship between diet and its effects 
on later-life disease through epigenetic mechanisms.   
 
Genistein, an isoflavone from soybeans, and bisphenol A (BPA), a chemical used 
in the manufacturing of polycarbonate plastics, have been shown to affect DNA 
methylation in the Avy allele.  In an interesting expansion of this classic mouse model of 
later-life disease and epigenetics, it was reported that the MS diet protects against BPA-
induced hypomethylation in F1 mice25. In this case, the viable agouti mice served as 
biosensors to environmental stressors that could alter the epigenome21, and secondly, it 
demonstrates how early-life diet (in the F0 generation) could impart disease risk or 
protection in the F1.  However, it should be noted that a different group tried repeating 
this MS diet and BPA study but reported insignificant results26.   
 
Methyl donor supplementation diet mice model (Ch. 3-5) 
Others have ventured to test similar variations of the MS diet in different 
contexts27.  The viable agouti mice are unique in that they possess the retrotransposon 
insertion that leads to ectopic expression of the agouti gene.  Therefore, these mice are a 
model of a unique genetic-epigenetic predisposition of obesity.  A study that followed the 
classic agouti mice papers set out to test a high folic acid supplement diet in non-agouti 
mice in conjunction with diet-induced obesity (DIO) and reported worsened metabolic 
outcomes in C57BL/6J male mice28.  There is some evidence this MS diet could also 
affect neuro-behavioral phenotypes such as its reversal of alcohol-induced DNA 
methylation changes on Igf229.  However, high folic acid supplementation in C57BL/6J 
mice has also been associated with an increase of anxiety-like and hyperactive 
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behavior30.  MS diet in rats have been reported to exacerbate aspects of DIO and 
metabolic function through hypermethylation of the leptin promoter Ob, decreasing F1 
rat leptin levels31.  They also revealed that MS diet was associated with impaired post-
natal growth, and male rats displayed increased long-term body weight gain—potentially 
due to the suppression of leptin expression31.   
 
Our lab has previously shown that a MS diet, closely modeled to the classic 
agouti mouse studies, is protective in an atherosclerosis mouse model32.  Apolipoprotein 
E ApoE(-/-) deficient mice spontaneously develop atherosclerotic lesions, and MS pre- 
and peri-natal diet exposure decreases T-cell mediated pro-inflammatory cytokine and 
chemokine responses in F1 mice.  Ccr2 is important for the inflammatory pathogenesis of 
atherosclerosis.  In a subsequent study, MS diet F1 mice have increased global CD3+ T 
cell methylation and Ccr2 expression was significantly reduced33.   
 
The MS diet has also been shown to affect gut microbiota and inflammation in a 
mouse model of human inflammatory bowel disease34,35.  In this study, the authors 
showed that a chemically-induced colitis with dextran sulfate sodium (DSS) is 
exacerbated in F1 mice whose parents were on the MS diet.  In a later experiment, they 
showed that cage swapping to enable a fecal microbiome transfer between MS diet and 
germ-free mice was sufficient to worsen colitis, compared to a control diet and germ-free 
cage swap control group34.  These studies on MS diet and host gut inflammatory 
responses differ from the obesity studies in that they show that the MS diet could affect 
later-life disease in avenues other than DNA methylation and instead, through the gut 
microbiome.   
 
Diet, the microbiota, and colonization resistance (Ch. 3-4) 
 Gut microbiota, the gastrointestinal resident microbial community, is important 
for colonization resistance36,37 and host immune responses38.  The primary risk factor 
Clostridium difficile infection (CDI), which is the most common nosocomial pathogen in 
the United States, is antibiotic-use39–42.  Non-antibiotic associated CDI is on the rise43, 
prompting new studies to search for other major risk factors.  In the last few years, the 
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effect of diet on gut microbiota has been shown to be a potential contributor to the rise of 
CDI, especially the hypervirulent strains of C. difficile44,45.   
 
 Diet as a transient stimulus has shown to induce changes in the microbiota in 
humans.  In mice, an excess of zinc in a diet drastically alters the gut microbiota and with 
an additional antibiotic challenge, colonization resistance against C. difficile was lost45.  
Whereas, control mice on a low-dose zinc diet with the antibiotic challenge maintained 
colonization resistance, thereby preventing CDI.  The zinc diet study demonstrates that 
metal levels in environment, in this case diet, can directly alter gut microbiota through 
metal-toxicity reduction of microbial diversity or microbial homeostasis and lead to 
changes in host health outcomes.    
 
Another recent study revealed that the hypervirulent C. difficile strains RT027 and 
RT078 gain significantly higher fitness in the presence of a sugary substitute in processed 
foods, trehalose, that likely aided in its successful spread in North American and West 
Europe44.  The trehalose study shows that diet could also shift microbial composition 
through means of increased fitness for specific microorganisms as opposed to reduction 
of other microbial populations as in the zinc study.  The role that diet plays in later life 
disease through various epigenetic mechanisms currently remain unclear, but the recent 
studies that demonstrate the significant and differential ways in which diet could alter gut 
structure and function indicate that diet is no minor player.   
 
Obesity in the Young and Old (Ch. 2 & 5) 
Adipose, or fat tissue, is the largest endocrine organ in humans and in other cases, 
can be the largest organ in an obese individual.  Adipose tissue plays a pivotal role in 
age-related metabolic dysfunction and longevity46–48.   With old age, fat distribution shifts 
from subcutaneous to visceral fat depots, while triglycerides ectopically deposit on liver, 
muscle, bone marrow, and heart49.  These changes are associated with the development 
and progression of a variety of age-associated diseases.   
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Obesity accelerates the onset of these age-associated diseases, further 
emphasizing the level of impact adipose tissue plays in aging46,50.  Similar to 
inflammaging, obesity is linked to a systemic, chronic, low-grade inflammation.  Adipose 
tissue inflammation in obesity is also termed ‘metaflammation’51.  While most recent 
studies focus on how adipose tissue dysfunction progresses in diet-induced obesity, much 
less efforts have been devoted to understanding the pathogenic mechanisms of old-age 
obesity. Whether inflammaging and metaflammation share common inflammatory 
pathways or have similar sources of inflammation, including the role of different fat 
depots, are important questions.  It is likely there are fundamental differences between 
diet- versus age-dependent obesity, given the widespread immunological and 
physiological changes that are known to occur in old age.   
 
The majority of interventions that extend lifespan function through nutrient 
sensing and processing pathways, and they have important effects on adipose tissue 
formation and function. Growth hormone deficient mice, in addition to improved 
lifespan, have less ectopic fat deposition, improved adipocyte progenitor cell function, 
and reduction in cellular senescence50.  A number of single-gene mutations are known to 
extend lifespan in lower organisms, and similar lifespan extension is observed even if the 
mutations are restricted to adipose tissue52–54. 
 
Obesity paradox and aging 
The obesity paradox refers to a collection of unexpected findings, where several 
chronic diseases, including cardiovascular, have lower all-cause mortality rates in 
elevated body mass index (BMI) patients55.  The “obese healthy” implicates that having a 
higher BMI can be protective and that the “lean” BMI is in actuality, not the lowest 
mortality group.  For example, obese (BMI >30 kg/m2) and severely obese (BMI >40 
kg/m2) patients after coronary artery bypass grafting are at lower risk for postoperative 
complications than patients with a lower but “normal” (18.5 kg/m2 < BMI <25 kg/m2) 
categorization55.  It has been controversial as to how this can occur—and many of these 
observations were thought to be particularly true in elderly patients.  It is reasonable to 
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postulate that, in some circumstances, adiposity may confer a degree of biological 
resiliency that enhances recovery after a stressful life event. 
 
Studies described the mortality risks as a ‘U-shaped curve’ for the elderly while 
the younger individuals have a ‘check-mark’ or ‘j’ shape mortality curve.  Where 
increased BMI in the overweight and even obesity ranges have exhibited protective 
effects on patients, although true in the datasets, also held many caveats in the design 
study.  When body composition was measured using a different method, it seems BMI 
frequently misclassifies body fat status, and it was argued that BMI is a better predictor 
of lean body mass than of adiposity55.  Therefore, patients with higher BMI are protected 
by higher lean body mass and not body fat.   
There are many other prominent theories summarized55,56—with some arguing 
that lean individuals plagued with chronic conditions could also be suffering 
‘malnutrition-inflammation complex syndrome’ which would be worse than carrying a 
high BMI.  It was also hypothesized that young obese with abdominal obesity die earlier 
and those who survive towards higher age categories like those of the obesity paradox 
studies actually carry greater degree of lower-body obesity.  Alternate theories suggest 
muscle quality determined by muscle mass and grip strength would also be important 
indicators of health55,56.  Others suggest genetic predisposition contributes to the 
formation of these obese healthy56 or metabolically obese57 phenotypes observed.   
 
Metaflammation (diet-induced obesity in the young) (Ch. 5) 
Adipose Tissue Immunological Profile During Diet-induced Obesity 
In obesity, adipose tissue homeostasis is perturbed:  the balance between energy 
intake and expenditure is pushed towards the former.  In aging, there is also a reduction 
in resting metabolic rate and lower total daily energy expenditure, particularly in frail 
individuals58.  With excessive accumulation and expansion of adipose tissue in obesity, 
there is an increased likelihood of metabolic syndrome, cardiovascular disease and type 2 
diabetes mellitus54.  Adipose tissue inflammation, specifically white visceral-gonadal 
adipose tissue, is a major contributor to metaflammation and insulin resistance. 
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Compared to lean individuals, white adipose tissue (WAT) from obese adults secretes 
higher levels of tumor necrosis factor α (TNFα), an inflammatory cytokine capable of 
interfering insulin signaling.  When TNFα is inhibited, glucose tolerance and insulin 
sensitivity is improved59.  Pro-inflammatory cytokines and chemokines such as 
interleukin 1b (IL-1b), monocyte chemoattractant protein (MCP-1), and interleukin 6 (IL-
6) are also secreted at elevated levels from obese adipose tissue macrophages60,61.   
 
Adipose Tissue Macrophages, Inflammation, and Organelle Stress 
Aging is associated with important changes in the innate immune system.  
Macrophages perform important innate immune functions including phagocytic clearance 
of dying cells.  Depending on the stimuli, macrophages can become polarized into “M1” 
or “M2” subsets. Classically-activated or M1 “killer” macrophages and alternatively 
activated M2 “healing” macrophages are convenient terms that describe the plasticity of 
macrophage subsets and function.  However, it is important to note that macrophages 
may not form clear-cut activation subsets nor expand clonally62.  Studies aimed to 
elucidate the source of inflammation in obesity have found that macrophages accumulate 
in WAT63 and exhibit a predominantly proinflammatory “M1” profile, as compared to the 
less or anti-inflammatory “M2” in lean healthy control adipose tissue60,61.  Hypertrophy 
and hypoxia also leads to the formation of crown-like structures where macrophages 
surround a dead or dying adipocyte64.  This very characteristic crown-like structure is 
used as one means of quantifying levels of inflammation in adipose tissue and has been 
shown to persist in the tissue even with weight loss in mice65.   
 
In obesity, adipose tissue macrophages are burdened with an increase in adipocyte 
death, leading to inflammasome activation, and formation of crown-like structures in the 
adipose.  Diet-induced obesity has also been shown to increase endoplasmic reticulum 
(ER) stress in mice, involving all 3 major branches of the unfolded protein response 
(UPR)—BIP, CHOP, and ATF466,67.  The higher ER stress responses involving IRE1α 
and CHOP has recently been shown to directly lead to stress-induced polarization of 
macrophages68,69 away from the M2 state, contributing to the domination of M1 
polarization in adipose tissue.   
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Outside of macrophages, the immune cell profile of obese WAT undergoes a 
multitude of other changes.  CD4+ and CD8+ effector T cell ratios also shift towards 
CD8+ T cells—a significant number of CD8+ T cells infiltrate the adipose tissue while 
CD4+ T cell numbers remain low70 during diet-induced obesity.   It is also suggested that 
this is how T cells can initiate adipose tissue inflammation via recruitment and 
stimulation of resident ATMs70.  Of note, regulatory T cells (Tregs) in the adipose tissue 
are also reported to be diminished in lean animals when compared to obese71.  Other 
studies have also reported on how eosinophils promote adipose tissue inflammation via 
supplying ATMs with a steady source of IL-4 in the tissue72.   While similar to CD8+ T 
cells, B cells during obesity can accumulate in the adipose tissue and secrete pathogenic 
IgG, spurring further inflammation, insulin resistance, and glucose intolerance73.  Mast 
cells have been shown to also contribute to inflammation and insulin resistance via 
production of IL-6 and IFNγ74.  The immune profile of obese WAT all contribute to 
adipose tissue inflammation and sustenance of proinflammatory polarization of ATMs.   
 
Non-immune Players in Adipose Tissue Inflammation 
As previously mentioned, adipose tissue is an endocrine organ.  Adipocytes can 
by themselves secrete adipokines which are chemokines and cytokines, some more 
unique to the adipose tissue and metabolism (e.g., leptin, adiponectin) while others are 
familiar to the immune system (IL-6, TNFα)75.  During obesity, adipocytes increase 
proinflammatory cytokine and chemokine secretion of IL-6 and TNFα, where TNFα has 
been shown to increase insulin resistance in diet-induced obese mice51.  Apart from 
immune cell infiltration, adipose tissue dysfunction in obesity is complicated by 
abnormalities of lipid metabolism76,77.   
 
While adipose dysfunction is not solely reliant on immune cell-driven 
inflammation, adipocyte function also cross-talks with immune cells and independently 
contributes inflammatory signals.  For instance, higher levels of circulating free fatty 
acids in obese conditions that undergo lipolysis generate saturated fatty acids (SFAs), 
proinflammatory lipid compounds that stimulate macrophage78, adipocyte79, myocyte80 
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and hepatocyte81 inflammation, leading to insulin resistance82–84.  SFAs activate 
macrophages via Toll-like receptor 4 (TLR4), but they are also precursors for ceramide 
biosynthesis which can directly decrease insulin sensitivity or indirectly affect insulin 
signaling through the production of Fetuin-A (FetA)85.  Interestingly, FetA null mice 
have protection against insulin resistance in an obesity and aging model as well86, and we 
recently report that TLR4 KO mice have a reduction in adipose tissue inflammation in 
aging87.  These findings indicate that while adipose tissue inflammation is primarily 
attributed to ATMs in literature, there are other non-immune players that similarly 
contribute and overlap in perpetuation of the inflammatory cycle in the adipose tissue.   
 
Inflammaging (age-associated obesity) (Ch.2) 
Loss of Basic Adipose Function 
With old age, adipose tissue distribution shifts towards visceral fat storage49.  
Patients with human immunodeficiency virus (HIV) also suffer loss of subcutaneous fat 
with an increase in visceral fat.  (HIV)-associated lipodystrophy leads to increased risk of 
CVD and diabetes, stressing the importance of subcutaneous-visceral adipose tissue 
distribution and metabolic health88.  Ectopic deposition of triglycerides also occurs on 
other organs such as liver, skeletal muscle, and even bone marrow49.  This trend is 
associated with higher risk of cardiovascular and metabolic disorders.   
 
Aging Adipose Tissue and Immunological Profile 
We have previously examined and characterized immune changes in WAT in old 
mice and found that in aging adipose tissue, similar to obesity, macrophages exhibit a 
shift away from M2 and towards double negative (CD206-CD11c-) expression89.  In this 
study, young and old mice adipose tissue was fractioned into ATMs (CD11b+), adipose 
tissue stromal cells (ATSCs) (CD11b-), and adipocytes.  These fractions were then 
individually analyzed for cytokine and chemokine production.  While all 3 fractions 
excreted IL-6 and MCP-1 in vitro, ATSCs and ATMs produced substantially higher 
levels, implicating that the major contributors to adipose tissue inflammation in aging are 
the resident fat immune cells and not adipocytes.   
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In a separate study, we investigated the role endoplasmic reticulum (ER) stress 
plays on macrophage inflammation in old adipose tissue.  Similar to obese ATMs, old 
ATMs also display elevated ER stress and inflammation90.  Alleviating the ER stress in 
old murine ATMs in vitro and in vivo via a chemical chaperone decreases the production 
of inflammatory cytokines and chemokines90.  Another study similarly employed 
chemical chaperones to reduce ER stress in the adipose tissue of diet-induced obese mice 
and succeeded decreasing adipose tissue inflammation91.  In a later investigation, we 
observed that old mice also possess perturbed autophagy function within their SVF, 
contributing to adipose tissue ER stress and inflammation.  Furthermore, blocking 
autophagy function in the SVF increased ER stress marker CHOP and pro-inflammatory 
markers IL-6 and MCP-192.  These results emphasize the importance of adipose tissue 
homeostasis and metabolism, particularly at how large of a role non-adipocytes can play.   
In old adipose tissue, there was also a higher total stromal vascular cells (SVF) 
per gram of WAT, showing that adipose tissue accumulates resident cells over time.  The 
increase in SVF was observed in T cells (CD3+), particularly CD4+ T cells and a minor 
increase in CD8+ T cells.  A three-fold increase of regulatory T cells (Tregs) was present 
in old WAT89.  Aging has been reported to be associated with increased Treg function 
secondary to age-related epigenetic drift and T cell DNA hypomethylation93. Excessive 
Tregs activity may contribute to age-related susceptibility to infection, 
neurodegeneration, and cancer94–96. The origin of the Tregs in aging adipose tissue is not 
defined but is presumably derived from peripheral naïve CD4 T cells responding to the 
local aging microenvironment.  Nevertheless, the results were unexpected as others have 
shown that visceral adipose tissue of lean animals have higher number of Tregs compared 
to their obese cohort.  The adipose tissue Tregs presumably playing a protective role in 
metabolic disorder, suppresses the production of local inflammatory mediators and 
improves insulin resistance71,97. Importantly, a recent study also showed that the 
depletion of these fat-specific Tregs prevent age-associated insulin resistance in mice98, 
supporting the notion that distinct immune cell subpopulations all play an inter-
connecting role in age-associated inflammation and diseases.   
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Human aging is in part, characterized by a chronic, low-grade inflammation that 
develops in various aging tissues.  This phenomenon is termed ‘inflammaging’99,100.  The 
health detriments and benefits of inflammaging are inconclusive.  While super 
centenarians boast a higher inflammatory cytokine profile101, inflammatory mediators are 
critical to the pathogenesis of age-related diseases such as arthritis, diabetes, sarcopenia, 
cardiovascular disease (CVD), cancer, and dementia102,103.  While sources of 
inflammaging remain under investigation, some prominent conversations include 
immunosenescence99,104, self-debris105, senescent cells106, mitochondria dysfunction107,108, 
microbiome109, and adipose tissue47,50,110.     
 
The Role of Fat Mass in Longevity (Ch. 2) 
Caloric restriction and the role of fat mass in lifespan 
In mammals, caloric restriction is the classic method of lifespan extension, and 
given that caloric restriction (CR) results in smaller growth and therefore reduced fat 
mass gain, it was believed that CR benefits stem from having less fat mass111.  In the last 
two decades, the growing literature on the wide range of functions of adipose tissue has 
become supportive evidence of fat mass’s influence on health48,112.  As previously 
discussed in the metaflammation and inflammaging sections of this chapter, the 
detrimental changes to adipose tissue in obesity have been likened to a state of 
accelerated aging47.  Whereas, inflammation in aging has been, in part, attributed to lipid 
redistribution49,113–116, ectopic fat deposition on various organs49,116,117, and immune 
changes to gonadal white adipose tissue89,90,93.  These collectively build into the notion 
that adipose tissue health, though not the sole factor, can determine an organism’s 
lifespan.   
  
Senescent cells in aging adipose tissue 
Senescence serves as the brakes to tissue renewal and cancer cell development in 
organisms.  More specifically, senescence is a process where cells become irreversibly 
arrested in cell-cycle to prevent further replication in response to stress118.  In aging, 
environmental stresses compound overtime: DNA damage, telomere attrition, mitogenic 
signals, and chromatin dysfunction lead to the accumulation of senescent cells in various 
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tissues118.  While senescent cells become non-replicative, they also undergo phenotypic 
changes, including tumor-suppressor and secretome switches119, that enable them to 
affect the tissue microenvironment, influencing neighboring cell structure and function.   
 
Two primary tumor-suppressor pathways, involving p53 and pRB, are attributed 
with regulating the senescent states of cells.  These transcriptional regulators are nestled 
in the center of the pathways, with stress response proteins upstream and downstream 
effectors that promote and maintain senescent states.  Loss of p53 function in studies 
have shown to diminish replicative senescence in human cells120 while inactivation of 
p21, a cell cycle inhibitor that is also a p53 target, allows cells to bypass telomere 
attrition-dependent senescence121.  The pRB pathway contains p16, a cell cycle inhibitor 
that responds to stress.  Senescence occurs with either pathway or both; however, 
downstream of these pathways, upregulated genes include secreted proteins that include 
cytokines and chemokines122.   
 
Senescent cells have been reported to secrete various proinflammatory cytokines 
such as IL-6, IL-8, and TNF-a, collectively known as the senescence-associated secretory 
phenotype (SASP)106.  These proinflammatory factors accumulate with aging, as the old 
immune system becomes less efficient with the clearance of senescent cells118,122.  They 
become a potential source of inflammation in inflammaging.  Recently, studies indicate 
that visceral and inguinal adipose tissue in mice harbor large quantities of senescent cells 
that are p16Ink4a positive123. Tissue accumulation of p16, p21, and β-galactosidase are 
markers of senescence, and senolytics are designed for the clearance of senescent cells 
that fail to be naturally cleared by the host immune system.  Recent senolytics studies 
successfully depleted p16Ink4a via a novel transgene, INK-ATTAC, and it was 
demonstrated that age-related disorders can be attenuated in the BubR1 progeroid mouse 
model123,124.   
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ITP Drug Interventions and Lifespan Extension (Ch. 2) 
 
 The Interventions Testing Program is an endeavor sponsored by the NIA to 
evaluate potential interventions in various forms (pharmaceuticals, nutraceuticals, foods, 
diets, dietary supplements, plant extracts, hormones, peptides, amino acids, chelators, 
redox agents, and other agents / mixtures of agents) that could extend lifespan, delay 
disease and dysfunction in mice (https://www.nia.nih.gov/research/dab/interventions-
testing-program-itp).    
 
Up until the year 2000, the National Institute of Aging (NIA) had been providing 
predominantly genetically homogenous aging mice either from inbred lines or F1 hybrid 
stocks.  Genetically heterogeneous mice were then generated via a four-way cross 
breeding scheme125,126 that generate “HET” mice from mating between (Balb/cJNia x 
C57BL/6JNia) F1 mothers and (C3H/JNia x DBA/2JNia) F1 fathers.  This results in no 
two mice that are genetically identical.  The goal behind the HET strain of mice is to 
enable the use of a mouse model where strain-specific idiosyncrasies can be untangled 
where experimental design allows for the use of heterogenous animals (for example, 
tissue transplantation would be infeasible in this mouse model).   
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Chapter 2 – Lifespan extension drug interventions affect adipose tissue 
inflammation in aging 
 
This chapter is in preparation for submission as a manuscript. 
 
Theresa Mau, Martin O’Brien, Amiya K. Ghosh, Richard A. Miller, and Raymond Yung.   
 
Abstract 
The National Institute on Aging-sponsored Interventions Testing Program (ITP) 
has identified a number of dietary drug interventions that significantly extend median 
lifespan, including rapamycin, acarbose, and 17-α estradiol.  However, these drugs have 
diverse downstream targets, and their effects on age-associated organ-specific changes 
are unclear 127.  Potential mechanisms by which these drugs may be extending life could 
be through their effect on inflammatory processes often noted in tissues of aging mice 
and humans. Our study focuses on the effects of three lifespan extension drugs in the ITP 
on inflammation in gonadal white adipose tissue (gWAT) of female and male HET3 
mice.  gWAT was harvested to study the drugs’ impact on adipose tissue inflammation—
including age-related fat mass gain, adipose tissue macrophage (ATM) M1/M2 
polarization, markers of cellular senescence and endoplasmic reticulum stress.  We 
observe that rapamycin led to a 56% increase of CD45+ leukocytes in gWAT, where the 
majority of these are ATMs.  Specifically, rapamycin led to a 217% and 106% increase 
of M1 (CD45+CD64+CD206-) ATMs in females and males, respectively.  We found that 
HET3 mice exhibit a spectrum of age-associated changes in the gWAT, but acarbose and 
17-α estradiol did not strongly alter these phenotypes.  Our data suggest that rapamycin 
may achieve lifespan extension in part through adipose tissue inflammation.  Our results 
also suggest that acarbose and 17-α estradiol may not influence lifespan through 
mechanisms involving adipose tissue inflammation. 
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Introduction 
Human aging is, in part, characterized by the tendency of the body to develop a 
proinflammatory status with advancing age 128–134.  Chronic inflammation plays an 
important role in the pathogenesis of many age-associated diseases 103,135,136, such as 
Alzheimer’s disease, atherosclerosis, cardiovascular disease, type II diabetes, and 
invasive cancer.  Adipose tissue inflammation is believed to be a major contributor to a 
range of age-related functional declines 47,48,112. Effects of abnormalities in adipose tissue 
could in principle be mediated by changes in energy storage, lipid metabolism, or 
production and secretion of adipokines and hormones.   
 
With advancing age in humans and rodents, adipose tissue mass increases through 
middle and early-old age, and white adipose tissue (WAT) redistributes from 
subcutaneous to intra-abdominal visceral depots49,113–116.  WAT also exhibits ectopic lipid 
infiltration in liver, muscle, and bone49,116,117—though rodent models of lipodystrophy are 
still being developed and lack female data 137–139.  In gonadal white adipose tissue 
(gWAT), the distribution of adipose tissue macrophage (ATM) subsets shift toward pro-
inflammatory phenotypes with age89,90,93.  We have previously shown that in gWAT of 
old (22 mo.) C57BL/6J male mice, ATMs shifted from an anti-inflammatory “M2” 
phenotype (CD206+) towards the pro-inflammatory “M1” (CD206-) phenotype when 
compared to young (6 mo.) controls 89.  This upward shift in M1:M2 ATMs ratio was 
associated with increased levels of pro-inflammatory chemokines and cytokines.  
Although the M1/M2 distinction over-simplifies a network of inter-related cell types of 
overlapping function, we will, for the purpose of discussion, refer to 
CD45+CD64+CD206- macrophages as "M1s" and CD45+CD64+CD206+ macrophages as 
"M2s" in this report.     
 
Our subsequent studies revealed that endoplasmic reticulum (ER) stress plays a 
significant role in ATM inflammation in aging-associated obesity.   Alleviation of ER 
stress in old murine-derived ATMs blocked secretion of interleukin-6 (IL-6), tumor 
necrosis factor-alpha (TNF-α), and monocyte chemoattractant protein-1 (MCP-1), 
restoring a phenotype to that of young ATMs 90,92.  Another notable source of 
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inflammation in aging adipose tissue is production of inflammatory cytokines by 
senescent cells, termed senescence-associated secretory phenotype (SASP). Relative to 
other tissues (brain, liver, colon, lung, pancreas, and heart), white adipose tissue, along 
with skeletal muscle and the eyes, is a major reservoir for p16Ink4a and senescence-
associated β-galactosidase (SA-β-Gal) senescent cell accumulation. There is some 
evidence that reduction of p16Ink4a senescent cells may attenuate the onset of age-related 
disorders, at least in a mouse model of progeria 123,124.   However, the inflammatory status 
of the specific aging tissues that seem to benefit from the senolytics were unexplored—
necessitating future work to question whether or not the reduction of senescent cells 
directly diminishes adipose tissue inflammation. 
 
Previous studies 140–146 of the ITP drugs have reported on the sex differences, 
extent of lifespan extension, and dose-dependent response using genetically 
heterogeneous HET3 mice.  In this system, 30% caloric or dietary restriction can extend 
life in female and male mice by 36% 147.  ACA, which blunts post-prandial glucose 
spikes, extends male lifespan by 22% and leads to an increase of only 5% in females 145.  
17aE2 does not extend lifespan of females but extends male lifespan by 19% 145.    Rapa, 
which inhibits the mechanistic target of rapamycin (mTOR) kinase, can extend lifespan 
in females by 26% and in males by 23% at the highest doses tested 140,141,143,148.  Further 
details on the NIA Interventions Testing Program are summarized127 
(https://www.nia.nih.gov/research/dab/interventions-testing-program-itp).   
 
These changes in aging adipose tissue collectively contribute to age-associated 
adipose tissue dysfunction which affects health and lifespan 149.  Interventions for 
lifespan extension target nutrient-sensing pathways that also have significant effects on 
adipose tissue in lower organisms50,52,111,150,151.  In a few cases, mutations that extend 
lifespan in lower organisms such as flies or worms, also lead to lifespan extension when 
the mutation is limited to adipose tissue 152,153.  Fat-specific insulin receptor knockout 
(FIRKO) mice have reduced fat mass, protection from age-associated obesity, and mean 
lifespan extended by 18% 154.  In the current study, we hypothesized that ITP 
pharmacological interventions, specifically acarbose (ACA), 17-α estradiol (17aE2), and 
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rapamycin (Rapa), may extend life by slowing or preventing age-related increases in 
adipose tissue inflammation.  We measure aspects of adipose tissue composition and 
function in six groups of HET3 mice (young, old, calorie restriction (CR), ACA, 17aE2, 
and Rapa), with emphasis on the levels of adipose tissue ER stress and the relative 
proportions of ATM subsets.  Additionally, we evaluate the effects of age on HET3 
mouse adipose tissue and whether any of the ITP drugs influence these age-related 
phenotypes.   
 
Materials and Methods 
Animals:  Breeding & Husbandry Protocol 
Genetically heterogeneous UM-HET3 mice were produced via a four way cross 
between CbyB6F1/J mothers (BALB/cJ x C57Bl/6J, JAX #100009) and C3D2F1/J 
fathers (C3H/J x DBA/2J, JAX #100004) at University of Michigan (UM) as previously 
described 125.  The mice were housed in pairs per cage from weaning, cages were 
inspected daily, and mice that died were not replaced.  At 4 months of age, F1 mice from 
different breeding pairs were randomly allocated to 2 control and 4 treatment groups:  
young and old controls; calorie-restriction (CR), Acarbose (Aca), 17-α-estradiol (17aE2 
or Est), and Rapamycin (Rapa) treatment groups.   
 
Control and Experimental Diets 
Breeding pairs were fed Purina 5008 chow. Young (4 mo.) and old (22 mo.) 
control mice were fed the Purina 5LG6 chow post-weaning and throughout.  Control and 
treatment diets were prepared by TestDiet, Inc., Purina Mills (Richmond, IN, USA).  For 
calorie-restriction mice:  22 months of age, 30% CR from 4 months of age.CR group 
were given an amount of food equal to 90% of the amount consumed by mice in the ad 
libitum control group (“AL” group) for 2 weeks. They were then shifted to 75% food 
availability for 2 weeks and then shifted to 60% food intake for the remainder of the 
experiment 155.  Acarbose 1000ppm:  purchased from Spectrum Chemical Mfg. Corp. 
Gardena, CA, USA; 22 months of age, Acarbose from 4 months of age.  17-a-Estradiol 
14 ppm:  purchased from Steraloids Inc. (Newport, RI, USA) 22 months of age, estradiol 
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from 9 months of age.  Rapamycin:  at 4 months of age were given a diet containing 
encapsulated rapamycin at 14.7 ppm (mg of drug per kg of food).   
 
Tissue extraction:  gWAT stromal vascular fraction 
Gonadal white adipose tissue (gWAT) is removed with minimal cuts, weighed, 
and placed into a sterile petri-dish containing ice cold dye-free Dulbecco’s Modified 
Eagle Medium (DMEM) containing 10% FBS (Gibco 21063-029) and 1% Penicillin 
Streptomycin (Gibco 15140-122).  Collagenase (Sigma Life Science, #C6885-1G) is 
prepared in DMEM buffer with a final 10mg/mL concentration.  gWAT fat pads were 
minced, gently passed through 100 μm filter, centrifuged (1500 RPM), and collagenase-
digested in an 37° C incubator for 45 min with rotation.  A second rinse-filter step 
follows.   ACK lysis (Lonza, #10-548E) is mixed into cell pellets and neutralized at 5 
minutes with ice cold PBS.  A third rinse-filter step occurs with cold PBS.  SVF cell 
fractions are resuspended in 1 mL of cold PBS and 10 μl is saved for trypan blue 
(Invitrogen) cell counting using the Cell Countess (Invitrogen). 
 
Flow cytometry stains 
SVF cells extracted from gWAT are washed and resuspended in sterile filtered 
FACs buffer (PBS, 0.5% BSA, 0.1% NaN3) and cells per sample are pooled together to 
form the control cells for Single Positive Controls (SPCs), Full-minus-one Controls 
(FMOs), and the negative cells.  Samples are blocked with anti-mouse CD16/CD32 
(eBioscienceaffymetrix #14-0161) for 1 hr on ice.  After rinsing, cells are incubated with 
anti-mouse CD45 (eBioscienceaffymetrix #48-0451), CD64 (BD Pharmingen 558455), 
CD11c (eBioscienceaffymetrix #47-0114), CD11b (eBioscienceaffymetrix #11-0112), 
CD206 (eBioscienceaffymetrix #17-2061), & CD31 (eBioscienceaffymetrix #46-0311) 
for 1 hr on ice, in foil.  Cells were fixed with 2% paraformaldehyde (PFA) for 20 min on 
ice prior to washing and storing in FACs buffer until analysis.  Samples were run on a 
LSRFortessa (University of Michigan Flow Cytometry Core) and analyzed on FlowJo 
version 10.0.0.1.  
 
 
21 
 
mRNA isolation and RT-qPCR 
Total RNA was isolated from whole adipose tissue (gonadal / inguinal depots), 
homogenized in Qiazol lysis reagent (Qiagen, #1023537), and processed through a 
QIAshredder (Qiagen, #79656) prior to using the RNeasy Lipid Tissue Mini Kit (Qiagen, 
#1023539) in conjunction with a RNase-Free DNase (Qiagen, #79254) digestion step.  
Reverse transcription and cDNA amplification was performed with QuantiTect SYBR 
Green RT-PCR Kit (Qiagen, #1054498) on a real-time R6-6006 Corbett Thermalcycler.  
All primers were obtained from IDT and specific primer sequences are listed (Table 1.1).   
 
Western blot 
Briefly, whole gWAT protein lysates were mixed with 4x Laemmli (Biorad #161-
0737), denatured, loaded at 40 μg per well into 15-well 4-20% gel casts (Biorad Mini-
PROTEAN TGX Precast Gels, #456-1096) and ran at 90V in a Tris/Glycine/SDS buffer.   
It was transferred to a PVDF membrane (BioradImmun-Blot, #1620177) in a 
Tris/Glycine/20% MeOH buffer at 100V.  Then, it is rinsed with TBS / 0.1% tween and 
blocked (Thermo Scientific Superblock T20, #37536) for 1 hr at RT on rotator.  Primary 
antibody (CHOP (anti-DDIT3 Abcam ab179823), P62 (Abcam ab9691526), or IgG (goat 
anti-mouse IgG-HRP Santa Cruz sc-2031), a-tubulin (Abcam ab18251)) is administered 
overnight in a 4°C cold room.  Blots were washed 3x 10 min with TBS / 0.1% tween 
prior to incubation with secondary antibody (in 5% non-fat milk powder in TBS/tween) 
for 30 min at RT on rotator.  Chemiluminescence is captured via Pierce ECL Western 
Blotting Substrate (Thermo Scientific, #32106) on Image Quant LAS 4000 (GE 
Healthcare) machine.  Densitometry is calculated with ImageJ software.   
 
Statistical Analyses 
2way-ANOVA analyses were performed, setting factor 1 = sex [female; male], 
factor 2 = [old controls; one of the following groups: young controls, CR-, ACA-, 17aE2-
, or Rapa-treated mice.  Interaction term = sex term x treatment term, each reported (* 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). A post-hoc test used as a follow-up 
was Sidak’s multiple comparisons, reporting average difference in mean for each sex (* 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).  If interaction or sex effect were 
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insignificant, sexes were pooled and submitted to normality tests D’Agostino & Pearson 
and Shapiro-Wilks (alpha=0.05).  If normality test passes (p≥0.05), then a Student’s 
unpaired T-test is run and if significant (^ p<0.05, ^^ p<0.01, ^^^ p<0.001, ^^^^ 
p<0.0001), reported degree of significance and average difference in mean.  If normality 
test fails (p≤0.05), then a Mann-Whitney test is run, and if significant (# p<0.05, # # 
p<0.01, # # # p<0.001, # # # # p<0.0001), degree of significance and average difference in 
median were reported. Values reported within text are mean ± SEM.  Where there are 
significant sex effects, percent change is reported within the text.  Occasionally, the 
follow-up Sidak’s comparisons test (for individual sexes) do not reach statistical 
significance and are denoted as not significant (N.S.), and these trends may be reported to 
highlight the sex effects and will be further explored in discussion.  P-values reported for 
interaction (sex*treatment), sex, or treatment represent 2way-ANOVA results which is 
comprehensively reported with the submitted manuscript, and further details on this table 
is within the statistical methods section.  In cases where the sex and/or interaction term in 
the 2way-ANOVA is insignificant, the mean ± SEM reported represent pooled sex data.  
Table 1 contains a concise summary of statistically significant findings.   
Results 
Genetically heterogeneous HET3 mice were assigned to either young or old 
controls. CR, ACA, 17aE2, and Rapa treatment began at 4 months of age with the 
exception of 17aE2 mice which were placed on 17aE2-treatment diet at 9 months of age 
(Figure 2-1A).   
 
Lifespan extension drugs and adiposity 
With age, the changes in rodent and human adipose tissue distribution and mass 
lead to an age-associated form of obesity 49,112,115,116.  HET3 mice steadily gain weight 
with advancing age, and we had previously observed that HET3 mice undergo age-
related weight decline beginning at approximately 18 months of age 143,148.  Similar to 
reports in human aging 115,116,156, advanced stages of aging in HET3 mice are 
characterized by a decline in body weight, and this was clearly present in males and to a 
lesser extent in females 145.  In this current study, we report HET3 mice weights at 22 
months of age, a time point that likely reflects a 4-month period of age-related decline in 
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body mass.  Consistent with previous studies, old control females (34.7 ± 1.71 g) weigh 
more than young control females (24.1 ± 0.6 g; p<0.001), while there are no significant 
differences in average body mass between old (36.0 ± 2.1 g) and young (37.1 ± 1.1 g) 
control males (Figure 2-1B).   
 
In CR mice, interaction between sex and treatment on body mass is significant 
(p<0.01). Old CR females have body masses (22.9 ± 0.4 g) similar to their young 
counterparts and weigh less than old control females (34.7 ± 1.7 g; p<0.0001) (Figure 2-
1B).  The age-associated loss of fat in old control males (36.0 ± 2.1 g) may be why these 
mice are statistically indistinct from old CR males (33.2 ± 1.5 g) in body mass.  
Consistent with our previous study 145, 17aE2-treated HET3 mice of both sexes have no 
significant body mass differences at 22 months of age.   ACA-treated mice also do not 
have changes to body mass when compared to old controls.  However, we have 
previously observed that ACA-treated females developed smaller body masses than old 
control females 145, therefore interpretation of this data should take this into account. In 
another study, when Rapa treatment was administered beginning at 9 months of age, we 
observed trends of smaller body weights at the highest dosage (42 ppm) while moderate 
dosage (14 ppm) induced no significant body weight changes in either sex 143.  In this 
current study, we observe that when Rapa treatment is prescribed at 4 months of age at 
the moderate dosage, by 22 months, total body mass of Rapa-treated female and male 
mice (39.1 ± 1.1 g) is significantly higher than old controls (35.2 ± 1.3 g; p<0.05).   
 
We next compared the masses of gonadal white adipose tissue (gWAT) from each 
mouse (Figure 2-1B).  The interaction between age and gender is significant for gWAT 
mass (p<0.01), indicating that at 22 months, gWAT fat pads are different between the 
two sexes.  Consistent with reported aging trends on visceral fat mass gain in humans 
49,116 and rodents 113,157, old female mice (2.4 ± 0.4 g) have larger gWAT pads than young 
females (0.7 ± 0.1 g; p<0.0001).  We observe no significant mass difference between 
young (1.4 ± 0.1 g) and old (1.3 ± 0.2 g) male fat pads.  Without gWAT measurements at 
12 and 18 months of age, we are unable to conclude whether male gWATs amassed 
differently with age than females or if their age-related decline in total body weight  
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Figure 2-1 – ITP drug interventions differentially influence gWAT and body mass ratio of 
HET3 mice. A) HET3 mice in drug-intervention timeline.  All mice were analyzed at 22 months 
of age except for young controls which were 4 months of age.  B) Total body mass and gWAT 
mass (1 fat pad per mouse) were measured, and gWAT to body mass ratios were calculated.  n=9-
19 per group of mice.  Error bars are SEM.  2-way-ANOVA, Sidak’s multiple comparison’s post 
hoc test (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).  If no sex effect was significant, 
sexes were pooled for analyses with either Student’s unpaired T-test (^ p<0.05, ^^ p<0.01, ^^^ 
p<0.001, ^^^^ p<0.0001) or by Mann-Whitney if normality tests failed, (# p<0.05, # # p<0.01, # # # 
p<0.001, # # # # p<0.0001). 
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heavily stems from gWAT mass loss.  There is a significant interaction between sex and 
CR in gWAT mass (p<0.05).  CR female mice (0.5 ± 0.1 g) develop smaller fat pads than 
old non-CR females (2.4 ± 0.4 g; p<0.0001), shifting them towards sizes similar to young 
females (0.7 ± 0.1 g).  ACA- and 17aE2-treated mice have a modest decline in fat pad 
sizes that did not reach statistical significance (Appendix 1).  In contrast, Rapa-treated 
female mice (5.0 ± 0.5 g) have a substantial increase in their fat pad masses compared to 
controls (2.4 ± 0.4 g; p<0.001), while Rapa-treated male mice (0.5 ± 0.1 g) are on 
average lower than controls (1.3 ± 0.2 g, N.S.).  Given this difference, interaction 
between sex and Rapa-treatment is highly significant (p<0.0001).  
 
To account for body mass differences, we also calculated the fat pad to body mass 
ratio for each mouse (Figure 2-1B).   In congruence with the fat pad and body mass 
analysis, this ratio is significantly increased between young (2.6 ± 0.4 %) and old (6.2 ± 
0.9 %; p<0.0001) females and not between young (3.6 ± 0.2 %) and old (3.3 ± 0.5 %) 
males.  CR treatment in female mice (2.0 ± 0.2 %) lead to smaller fat pad to body ratio 
than controls (6.2 ± 0.9 %; p<0.001), while ITP drugs ACA and 17aE2 do not affect 
either sex.  In contrast, Rapa-treated female mice (12.1 ± 1.0 %) have an increase to their 
gWAT to body-mass ratio compared to controls (6.2 ± 0.9 %; p<0.0001).  This indicates 
in females, Rapa-treatment leads to gonadal fat pad expansion well-beyond the age-
related fat mass gain observed in old female controls.  Interestingly, while Rapa-treated 
female mice have a ~95% increase in gWAT to body mass ratio, Rapa-treated male mice 
(1.4 ± 0.2 %) have a ~58% decrease from old control males’ gWAT to body mass ratio 
(3.3 ± 0.5 %, N.S.). 
 
SVF density in gWAT is altered by certain ITP drugs 
To study the immune composition of the gWAT, we first separated the stromal 
vascular fraction (SVF) cells of the gWAT from the adipocyte fraction.  We have 
previously reported in C57BL/6J mice, there were increased gWAT SVF cells in old 
males (22 mo.) compared to young males (6 mo.) 89.  Here, we observe a significant 
effect of age in the gWAT SVF cell numbers of female HET3 mice (p<0.05).  Old 
females (4.0 x 106 ± 0.6 x 106 cells) have significantly higher total SVF count than young  
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Figure 2-2 – CR and Rapamycin alter gWAT cell density and CD45+ leukocyte frequencies 
differently. A) Stromal vascular fraction (SVF) total cell numbers are reported for each mouse, 
separated by sex.  n=9-19 per group of mice. On the right, SVF cell counts are normalized to each 
mouse’s gWAT mass which provides a cell density value as number of cells per 1 gram of 
gWAT.  B) Flow cytometry of gWAT leukocytes, endothelial cells, and cells enriched for 
ATSCs.  n=9-19 per group of mice.  CD45+ leukocyte frequency is reported as a percentage of 
the singlets gate, CD31+ endothelial cells and CD31- ATSC-enriched cells are reported as a 
percentage of the parent population CD45- cells.  Error bars are SEM.  2-way-ANOVA, Sidak’s 
multiple comparison’s post hoc test (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).  If no 
sex effect was significant, sexes were pooled for analyses with either Student’s unpaired T-test (^ 
p<0.05, ^^ p<0.01, ^^^ p<0.001, ^^^^ p<0.0001) or by Mann-Whitney if normality test failed, (# 
p<0.05, # # p<0.01, # # # p<0.001, # # # # p<0.0001).         
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females (1.3 x 106 ± 0.4 x 106 cells /mouse; p<0.001) (Figure 2-2A). CR mice (1.4 x 106 
± 0.1 x 106 cells) and 17aE2-treated mice (1.6 x 106 ± 0.4 x 106 cells) have lower SVF 
count than old controls (4.0 x 106 ± 0.5 x 106 cells; CR: p<0.0001, 17aE2: p<0.001).  
Rapa-treatment significantly increases total SVF in both sexes (6.6 x 106 ± 1.0 x 106 cells; 
p<0.05) (Figure 2-2A). Interestingly, CR- and 17aE2-treated mice have trends of shifting 
the SVF count down while Rapa-treatment appears to increase these cells in both sexes.   
 
To ask whether the density of SVF cells changes with age or ITP drug treatment, 
we normalized the total SVF cells per gram of gWAT mass in individual mice (Figure 2-
2A).   The density of gWAT SVF cells is sex- and age-dependent (interaction, p<0.05). 
Old females (1.6 x 106 ± 0.1 x 106 cells/g gWAT) have a significant decrease of gWAT 
SVF cell density compared to young females (2.9 x 106 ± 0.4 x 106 cells/g gWAT; 
p<0.01).  CR and ITP drugs ACA and 17aE2 do not alter SVF density.  Rapa-treated 
males (4.8 x 106 ± 1.2 x106 cells/g gWAT) have significantly increased SVF density 
compared to control males (3.9 x 106 ± 1.1 x 106 cells/g gWAT; p<0.001).   
 
gWAT SVF Immune Compartment  
The gWAT SVF cells that remain post-collagenase digestion contain 
preadipocytes, endothelial cells, immune cells, and other non-fat cells 72,89.  In humans 
and rodents, there is some evidence supporting the notion that SVF produces more 
proinflammatory mediators than adipocytes 89, which are known to also secrete 
adipokines and also contribute to inflammation 72.  In this study, we observe an increase 
of CD45+ leukocytes in the gWAT of old females (49.8 ± 3.0 %) compared to young 
females (40.4 ± 1.7 %; p<0.05), and no changes were noted between old (45.4 ± 2.5 %) 
and young (46.1 ± 2.0 %) males (Figure 2-2B). CR affects leukocyte frequency in a sex-
dependent manner (p<0.05) and leads to 26% and 38% decreased leukocyte frequencies 
in females (37.1 ± 2.0 %; p<0.01) and males (28.0 ± 1.3 %; p<0.0001) respectively.  
ACA and 17aE2 do not alter leukocyte frequencies in either sex.    When compared to old 
control mice (48.1 ± 2.1 %), Rapa-treated mice of both sexes have a substantial increase 
in CD45+ leukocytes (75.1 ± 3.5 %; p<0.0001).  We next analyze CD45- CD31+ 
endothelial cell numbers and find no overall differences, although old females (25.3 ± 1.6  
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Figure 2-3 – Lifespan extension drugs affect adipose tissue macrophage polarization.   
Flow cytometry of gWAT A) macrophages (CD45+CD64+) reported and B) dendritic cells 
(CD45+CD64-CD11c+).  n=9-19 per group and sex. C) Representative flow panel, n=2 per group 
and sex.  Gates: (y-axis) singlets > CD45+ > CD64+ > CD11b+ and CD206+ (x-axis).  “M1” 
(CD45+CD64+CD11b+CD206-) and “M2” (CD45+ CD64+ CD11b+ CD206+) macrophages 
reported as a % of CD45+ CD64+ cells.  Error bars are SEM.  2-way-ANOVA, Sidak’s multiple 
comparison’s post hoc test (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).  If no sex effect 
was significant, sexes were pooled for analyses with either Student’s unpaired T-test (^ p<0.05, 
^^ p<0.01, ^^^ p<0.001, ^^^^ p<0.0001) or by Mann-Whitney if normality test failed, (# p<0.05, # 
# p<0.01, # # # p<0.001, # # # # p<0.0001). 
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%) have a modest increase compared to young cohorts (18.4 ± 1.4 %; p<0.05).  CD45-
CD31- cells are analyzed as cells enriched for adipose tissue stem cells (ATSCs), but it 
appears none of the ITP drugs alter this compartment significantly.   
 
ITP drugs’ effect on adipose tissue macrophages 
Adipose tissue macrophages (ATMs) play a considerable role in adipose tissue 
inflammation 89.  Many studies of ATMs in mice have used markers such as CD11b and 
F4/80, which also identifies subsets of dendritic cells and eosinophils.  In an effort to 
disentangle these overlaps, the Immunological Genome Project identified a core murine 
macrophage marker, FcγR1 (CD64) 158.  It has been shown that CD45+CD64+ is specific 
for ATMs not only in C57Bl/6J male mice gWAT but also in human omental and 
subcutaneous adipose tissues 159.  In our data, there is no effect of aging on CD45+CD64+ 
ATM frequencies in either sex (Figure 2-3A)—similar to what we have previously 
reported in young (6 mo.) and old (22 mo.) C57BL/6J male mice 89.  CR mice of both 
sexes (51.0 ± 1.9 %) have a significant increase in ATM frequency compared to controls 
(40.5 ± 2.4 %; p<0.01).  Neither ACA nor 17aE2 alters the frequency of total ATMs.  
There is a sex difference with Rapa-treatment effects on total ATM frequency (p<0.05).  
Rapa-treated females (51.4 ± 4.4 %) have a 33% increase in ATM frequency compared to 
old females (38.6 ± 3.2 %; p<0.05), whereas Rapa-treated males (67.3 ± 4.3 %) have a 
55% increase compared to old males (43.5 ± 3.8 %; p<0.001).  Rapamycin significantly 
increases the proportion of CD64+ cells sufficient to account for the increase in total 
CD45+ cells in mice treated with this drug (Figure 2-3A, 2-4A).  We observe a sex- and 
age-dependent (interaction p<0.05) decrease of CD45+CD64-CD11c+ dendritic cells 
(DCs) in old males (14.9 ± 0.6 %) compared to young males (28.6 ± 2.9 %; p<0.0001) 
(Figure 2-3B). Of the three ITP drugs we test, only Rapa (6.4 ± 1.3 %) alters these DCs 
in males—shrinking this population by 57% when compared with old controls (p<0.001).   
 
In aged mice, ATMs shift towards M1-polarized “pro-inflammatory” 
macrophages, away from M2-polarized “anti-inflammatory” macrophages 89.  We 
observe a significant sex difference in age-associated ATM phenotypic switch in HET3 
mice (Figure 2-3C, Appendix 1).  These sex effects are present in both  
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Figure 2-4 –A) Flow cytometry frequency of gWAT CD64+ cells expressed as a percentage of 
singlets in HET3 female and male mice, n=9-19 per group and sex.  B) Flow cytometry frequency 
of gWAT non-macrophage, non-DC leukocytes (CD64-CD11c-) as a percentage of total CD45+ 
cells.  Error bars are SEM.  2-way-ANOVA, Sidak’s multiple comparison’s post hoc test (* 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). 
 
CD45+CD64+CD206- “M1” ATM frequencies (p<0.0001) and CD45+CD64+CD206+ 
“M2” ATM frequencies (p<0.0001). CR yield significant and modest sex effects on M1 
and M2 ATM frequencies (p<0.05 and p<0.05) as well.   
 
M1 Adipose tissue macrophages 
Old females (24.0 ± 4.8 %) have a 103% increase in M1 ATMs compared to 
young females (11.8 ± 2.1 %, N.S.), and old males (43.4 ± 8.8 %) have an 11% increase 
of M1 ATMs compared to young males (39.0 ± 3.5%, N.S.) (Figure 2-3C).  M1 ATMs 
in CR females (11.2 ± 4.2 %) decreases by 53% compared to old females (N.S.), and CR-
male mice (16.7 ± 4.5 %) have a 62% decrease in M1 ATMs compared to old males 
(p<0.01).  ACA and 17aE2 treated mice have M1/M2 shifts similar to CR, though 
Sidak’s multiple comparisons do not identify any significant changes in either sex.  In 
contrast, Rapa treatment leads to substantial increases to M1 macrophages in both 
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Figure 2-5 – Expression of A) ER stress genes (Bip, Chop, Atf4) and B) brite markers (Cd137 
and Prdm16) in gWAT, Error bars are SEM.  2-way-ANOVA, Sidak’s multiple comparison’s 
post hoc test (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).  If no sex effect was 
significant, sexes were pooled.  Student’s unpaired T-test (^ p<0.05, ^^ p<0.01, ^^^ p<0.001, 
^^^^ p<0.0001) or by Mann-Whitney if normality test failed, (# p<0.05, # # p<0.01, # # # p<0.001, # 
# # # p<0.0001).   n=9-19 per group and sex and each sample was normalized to Gapdh. 
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sexes (Figure 2-3C) and modest sex differences in M1/M2 ATMs (p<0.05, Appendix 1).  
Rapa-treated females (76.1 ± 5.3 %) have a 217% increase of M1-polarized ATMs 
compared to old controls (p<0.0001), and similarly but to a lesser extent, Rapa-treated 
males (89.2 ± 3.9 %) have a 106% increase to their M1 ATM population (p<0.0001). 
 
M2 Adipose tissue macrophages 
Naturally, the shifts in M1-polarization (CD206- ATMs) have a proportional 
switch in M2-polarization (CD206+ ATMs) in these mice (Figure 2-3C).  Old females 
(70.0 ± 5.0 %) have a 17% decrease of M2 ATMs compared to young females (83.8 ± 2.5 
%; N.S.), whereas old males (50.5 ± 8.8 %) have an 8% decrease of M2 ATMs compared 
to young males (54.7 ± 3.6%; N.S.).  CR increases M2 ATMs 20% compared to old 
females (83.8 ± 5.3 %; N.S.) and 55% M2 ATMs compared to old males (78.4 ± 5.0 %; 
p<0.01).  Compared to old controls, Rapa-treated females (18.1 ± 4.6 %) have a 74% 
decrease of M2-polarized ATMs (p<0.0001), and Rapa-treated males (7.5 ± 3.2 %) have 
an 85% decrease to their M1 ATM population (p<0.0001).  In addition, Rapa-treated 
mice have a 24% and 37% decrease in frequency of non-macrophage and non-dendritic 
cell leukocytes (T and B lymphocytes, eosinophils, etc.) that were CD45+CD64-CD11c- 
in females (p<0.05) and males (p<0.05) respectively (Figure 2-4B). 
 
ER stress responses in gWAT contribute to adipose tissue inflammation in aging.  
To determine if ITP drugs modify adipose tissue ER stress, we evaluate mRNA for Bip, 
Atf4, and Chop (Figure 2-5A). Old control mice of both sexes (1.8 ± 0.4 AU) have 
increased Chop compared to young controls (1.2 ± 0.3 AU; p<0.01).  CR improves ER 
stress responses in old HET3 mice: Chop is significantly reduced in both sexes (0.7 ± 0.1 
AU; p<0.0001). CR females (1.9 ± 0.3 AU) also have significantly decreased Atf4 
compared to old controls (3.3 ± 0.6 AU; p<0.05).  ITP drugs ACA and 17aE2 do not 
appear to affect lifespan extension through ER-stress in the adipose tissue.  Whereas, 
Rapa-treated females (3.5 ± 0.5 AU) have an increase in Bip compared to old females 
(2.3 ± 0.5 AU; p<0.05), and Rapa-treated females (9.6 ± 3.0 AU) also have an increase in 
Atf4 compared to old females (p<0.05).  Overall, we conclude ITP drugs we tested do not 
alter ER stress in gWAT, with the possible exception of Rapa treatment in females.   
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It has been postulated that age-related declines in browning and beiging adipose 
tissue activity in humans 160 and rodents 161,162 are contributing factors to age-related 
adiposity.  To test if 1) old HET3 mice have an effect of age on gWAT thermogenic 
factors and whether or not 2) any ITP drugs modulated them, we measured mRNA of 
beige or “brite” (browning of WAT) markers in unstimulated whole gWAT (Figure 2-
5B).  We measure CD137, a beige-selective marker 162 and zinc finger protein PR domain 
containing 16 (Prdm16) which is crucial for browning of WAT 163.   CR leads to 
decreased CD137 in both females and males (0.7 ± 0.1 AU) compared to old controls (1.8 
± 0.3 AU; p<0.001).  Rapa leads to increased CD137 expression (Rapa: 2.9 ± 0.3 AU, 
old: 1.8 ± 0.3 AU; p<0.01).  Old females (1.2 ± 0.1 AU) have lower Prdm16 than young 
females (2.5 ± 0.3 AU; p<0.001). CR decreases Prdm16 in females (CR: 0.4 ± 0.1 AU, 
old: 1.2 ± 0.1 AU; p<0.01) and males (CR: 0.8 ± 0.1 AU, old: 1.9 ± 0.4; p<0.01).  ACA-
treated females (2.4 ± 0.4 AU) have a modest increase of Prdm16 compared to old 
females (1.2 ± 0.1 AU; p<0.01).  Rapa-treated mice increases Prdm16 in both females 
and males (Rapa: 2.9 ± 0.4 AU, old: 1.4 ± 0.2 AU; p<0.0001).  The ITP drugs we tested  
appear to moderately affect the basal levels of thermogenic markers in gWAT, though it 
is likely the lifespan extension from these drugs are independent of these factors.   
 
Accumulation of senescent cells in iWAT 
Senescent cells accumulate in aging adipose tissue, particularly in the inguinal 
white adipose tissue (iWAT), and they play a role in determining lifespan and healthspan 
123,124. We measure p16, p21, and p53 in the iWATs of HET3 mice (Figure 2-6) to assess 
if there is an effect of age on the accumulation of these senescent cells in these 
genetically heterogeneous mice.  Both p16 and p21 are cell cycle inhibitors, and p53 is a 
primary tumor-suppressor pathway; these are important for the regulation of certain 
senescent states of cells 118,120,121,164. Consistent with literature 123,124,165, we observe an 
age effect on senescent cell accumulation in iWAT (Figure 2-6). Old female mice have 
age-dependent increases of p16 (young: 0.5 ± 0.1 AU, old: 2.5 ± 0.2 AU; p<0.0001) and  
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Figure 2-6 – Effect of aging on iWAT expression of senescent markers. Expression of 
senescence marker genes (p16, p21, and p53) in iWAT of HET3 mice. n=9-19 per group per sex.  
Each sample was normalized to Gapdh. Error bars are SEM.  2-way-ANOVA, Sidak’s multiple 
comparison’s post-hoc test (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).  If no sex effect 
was significant, sexes were pooled for analyses with Mann-Whitney if normality test failed, (# 
p<0.05, # # p<0.01, # # # p<0.001, # # # # p<0.0001).    
 
p53 (young: 1.2 ± 0.2 AU, old: 2.2 ± 0.2 AU; p<0.0001).  Both old females and males 
(2.3 ± 0.4 AU) have an age-dependent increase of p21 when compared to young controls 
(1.3 ± 0.1 AU; p<0.05). CR female mice (0.5 ± 0.1 AU) have significantly decreased p16 
compared to old females (p<0.0001), and CR females also have decreased p53 (CR: 0.6 ± 
0.2 AU, old: 2.2 ± 0.2 AU; p<0.0001), and CR mice of both sexes (0.7 ± 0.1 AU) also 
have decreased p21 compared to old controls (2.3 ± 0.4 AU; p<0.0001) (Figure 2-6).   
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Discussion 
The Interventions Testing Program within the National Institute of Aging is 
designed to identify treatments with the potential of lifespan extension and delaying 
disease and dysfunction in mice.  The 3 drugs we elected to test in this study, rapamycin 
(Rapa), Acarbose (ACA), and 17α-estradiol (17aE2) have all been shown to extend 
lifespan in mice.  ACA and 17aE2 primarily benefit males, whereas Rapa extends 
lifespan in both sexes.  These 3 drugs have been shown to affect a multitude of health 
outcomes in HET3 mice 142,143,145,146,148,166–168.  However, the underlying mechanisms and 
organ-specific effects remain to be fully explored.  How ITP drugs influence the aging 
processes and whether the different drugs influence lifespan through the same or different 
mechanisms are unclear.   
 
Caloric restriction (CR) is the classic approach that increases lifespan in healthy 
mice and has been regarded as the standard intervention for mammalian lifespan 
extension.  CR increases lifespan of HET3 mice by 32-47% 147.  Though not sufficient to 
completely explain CR-associated lifespan extension, it has been posited that CR may 
influence lifespan through the loss of fat mass111.  Of note, the three ITP drugs we tested, 
Rapa, ACA, and 17aE2, have been associated with different metabolic outcomes in 
HET3 mice143,169.  However, very little is known about the effects of these drugs on 
adipose tissue.  Given the important role of adipose tissue inflammation on age-related 
diseases, we hypothesized that these drugs’ effect on adipose tissue inflammation could 
be an important mechanism in lifespan extension.   
 
Adipose tissue macrophages (ATMs) are the major contributors to inflammation 
and metabolic dysfunction in diet-induced obesity 51,61,63.  In age-related adiposity and 
metabolic syndrome, gWAT undergoes phenotypic switching from anti-inflammatory 
“M2” towards pro-inflammatory “M1” macrophage polarization 89.  Interestingly, our 
data demonstrate old control HET3 mice have the greatest variability in the immune 
profile.  In particular, old control female mice separate into two groups—those with high- 
(~90%) and low- (50-70%) CD206+ frequencies.  Our data also suggest that only ~65% 
of old females develop a phenotypic switch from M2 to M1 with age.  Therefore, even 
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though a majority (~65%) of old control females have a lower average M2 macrophage 
frequency than 4 other female groups in the study (young control, CR, ACA, and 17aE2), 
the average of old females include the minority high expressers, masking important 
interpretations to this data.  We further postulate that CR and two ITP drugs, ACA and 
17aE2, skew macrophage polarization towards M2 by preferentially targeting old mice 
that express low CD206+ frequency.  Similarly, old control male mice show a significant 
variation in ATM polarization.   
 
In this study, we show that long-term dietary rapamycin fed to HET3 mice leads 
to significant M1 ATM polarization in the gWAT.  Along these lines, we also observe 
that the increase in CD45+ leukocytes in the adipose tissue of Rapa-treated mice is due to 
an increase in total macrophages (CD45+CD64+).  Given the role of M1 ATMs in 
metabolic inflammation and diabetes, the observation is consistent with studies that have 
shown rapamycin induces glucose intolerance in old rats, old C57BL6/J mice, as well as 
old and young HET3 mice 143.  Additionally, female and male HET3 mice developed 
hypoglycemia with both short- and long-term dietary rapamycin, but insulin sensitivity 
remained intact in both young and old mice 142.  This is unexpected, given the known 
association drawn between the proinflammatory “M1” macrophage and insulin resistance 
in the young, diet-induced obesity context 170.  In vitro, Rapa-treatment induces a 
phenotype switch in macrophage cell-lines from M2- to M1-polarized and nearly 
eliminates CD206+ expression in primary human macrophages 171. Our data is consistent 
with these studies—Rapa-treatment in HET3 mice strongly polarizes ATMs toward M1, 
significantly reducing the M2 macrophage compartment. Both ACA and 17aE2 
treatments cause a trend of M2 polarization increase in old male mice, although the 
results do not reach statistical significance.  This resonates with studies that have shown 
improved metabolic responses in male HET3 mice treated with ACA and 17aE2 169.  In 
CR males, there is significantly higher M2 polarization than non-CR old males, and while 
this trend was also present in females, it did not reach statistical significance.  Again, this 
aligns with the association of CR to improved metabolic responses 143.   
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When we assayed white adipose tissues for ER stress response genes (Bip, Chop, 
Atf4), beige/browning markers (Cd137, Prdm16), and senescent cell markers (p16, p21, 
p53), we find that the three ITP drugs we tested (Rapa, ACA, and 17aE2) did not 
substantially affect these aging adipose tissue phenotypes.  As expected, CR mice 
strongly resist the effect of normal aging on these markers in adipose tissue.  We 
previously reported old BL/6J male mice have increased gWAT ER stress responses 
when challenged with thapsigargin ex vivo, leading to enhanced release of pro-
inflammatory cytokines and chemokines in SVF cells and ATMs. In vivo, we reduced the 
secretion of these pro-inflammatory factors from the gWAT SVF with a chemical 
chaperone 90,92.  In this current study, we find that Chop mRNA levels are increased in 
old controls while CR mice have reduced Chop.  In contrast to the CR mice, Rapa-treated 
females have an increase in Bip and Atf4 mRNA.  Our data suggest that the three ITP 
drugs we tested do not facilitate lifespan extension through alterations on ER stress 
responses in aging adipose tissue.  Although there are sex differences in gWAT browning 
and beiging marker expression, we did not detect a strong effect of age in the HET3 mice.  
We find that consistent with published literature 123,124, we detected higher number of 
senescent cells p16, p21, or p53 in old HET mice inguinal WAT (iWAT).  As expected, 
CR mice of both sexes have significantly lower senescent cell accumulation in iWAT.  
The three ITP drugs we tested did not alter the expression of senescent markers in the 
HET3 mice.  Based on this data, we conclude that lifespan extending effect of the ITP 
drugs, Rapa, ACA, and 17aE2, is likely to be independent of senescent cells’ 
accumulation in white adipose tissue. 
 
An important limitation of our study is that we were only able to assay the HET3 
mice at the 22-month time point.  Male HET3 mice are shorter lived than their female 
counterparts, and weight loss has been a common phenomenon in male HET3 mice 
beginning at approximately 18 months of age 143,144,148.  Whereas, old female HET3 mice 
had displayed a much lesser extent of weight loss or weight loss appears to occur in the 
final few weeks of life 143,144,148.  Consistent with published data, we found that aging has 
an important effect on HET3 female mice adipose tissue inflammation.  In contrast, the 
changes in the old male mice were less pronounced.  The sex difference in old control 
38 
 
males in our study may therefore represent survival effects of the cohort.  This may 
explain how old control males also have similar body weights as old CR males and young 
control males.   
 
In summary, we found that CR and Rapa treatments influence aging adipose 
tissue inflammation differently. These observations add support to the notion that CR and 
Rapa treatments confer lifespan extension in distinct ways 143.  Our data also show ACA 
and 17aE2 generally did not influence any aspects of adipose tissue biology that we 
examined.   Overall, this study indicates out of the 3 ITP drugs selected, only Rapa 
treatment affects adipose tissue inflammation, possibly exacerbating it, in both sexes of 
HET3 mice.  Additional studies will need to be done to determine whether or not these 
Rapa-associated ATM changes directly contribute to lifespan extension.  Future studies 
of adipose tissue biology of aging should take into account sex differences in age-related 
adiposity changes.     
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Table 1 – Summary of dietary-drug interventions effect on aging adipose tissue 
 
 
 
 
 
 
 
 
 
 
 
Table 2 – Sequences for RT-PCR primers used in this chapter 
 
Phenotype Age Effect CR ACA 17aE2 Rapa 
 ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ 
Body mass ↑ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↑ ↑ 
gWAT mass ↑ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↑ ↔ 
gWAT/body % ↑ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↑ ↔ 
SVF cells ↑ ↔ ↓ ↓ ↔ ↔ ↓ ↓ ↑ ↑ 
SVF/ 1 g gWAT ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ 
CD45+ ↑ ↔ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↑ 
CD45- CD31+ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
CD45- CD31- ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
CD45+ CD64+ ↔ ↔ ↑ ↑ ↔ ↔ ↔ ↔ ↑ ↑ 
CD45+ CD64- CD11c+ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↓ 
CD64+ CD206- ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↑ ↑ 
CD64+ CD206+ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↓ ↓ 
CD64- CD11c- ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↓ ↓ 
Bip ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ 
Chop ↑ ↑ ↓ ↓ ↔ ↔ ↔ ↔ ↔ ↔ 
Atf4 ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↑ ↔ 
Cd137 ↔ ↔ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↑ 
Prdm16 ↓ ↔ ↓ ↓ ↑ ↔ ↔ ↔ ↑ ↑ 
p16 ↑ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
p21 ↑ ↑ ↓ ↓ ↔ ↔ ↔ ↔ ↔ ↔ 
p53 ↑ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
Gene of 
Interest Forward 5’  3’ Reverse 5’  3’ 
Bip GAGACTGCTGAGGCGTATTT CAGCATCTTTGGTTGCTTGTC 
Chop TCACACGCACATCCCAAA CCTAGTTCTTCCTTGCTCTTCC 
Atf4 CCACTCCAGAGCATTCCTTTAG CTCCTTTACACATGGAGGGATTAG 
p16 CATGTTGTTGAGGCTAGAGAGG CACCGTAGTTGAGCAGAAGAG 
p21 AAGTGTGCCGTTGTCTCTTC AGTCAAAGTTCCACCGTTCTC 
p53 GCCATGGCCATCTACAAGAA AATTTCCTTCCACCCGGATAAG 
Prdm16 GGGCCCTTGTAAACAACAAA GTCGGTCCTTCCTTGGTGTA 
Cd137 GCAGCCTGCAGGAACTTATC CCATTTCTGTCCCTTTTCCA 
Gapdh AACAGCAACTCCCACTCTTC CCTGTTGCTGTAGCCGTATT 
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Chapter 3 – Outbreak of murine infection with Clostridium difficile associated with 
the administration of a pre- and peri- natal methyl-donor diet  
 
This chapter has been submitted and is under review for publication. 
 
Theresa Mau, Samantha S. Eckley, Ingrid L. Bergin, Katie Saund, Jason S. Villano, 
Kimberly C. Vendrov, Evan S. Snitkin, Vincent B. Young, and Raymond Yung. 
 
Abstract 
Between October 2016 and June 2017, a C57BL6/J mouse colony that was 
undergoing a pre- and peri-natal methyl-donor supplementation diet intervention to study 
the impact of parental nutrition on offspring susceptibility to disease was found to suffer 
from an epizootic of unexpected deaths.  Necropsy revealed the presence of severe 
colitis, and further investigation linked these outbreak deaths to a Clostridium difficile 
strain of ribotype 027 we term 16N203.  C. difficile infection (CDI) is associated with 
antibiotic use in humans. Current murine models of CDI rely on antibiotic pretreatment to 
establish clinical phenotypes.  In this report, the C. difficile outbreak occurs in F1 mice 
linked to alterations in the parental diet. The diagnosis of CDI in the affected mice was 
confirmed by cecal/colonic histopathology, presence of C. difficile bacteria in 
fecal/colonic culture, and detection of C. difficile toxins.  F1 mice from parents fed the 
methyl-supplementation diet also had significantly reduced survival (p<0.0001) than F1 
mice from parents fed the control diet.  When we tested the 16N203 outbreak strain in an 
established mouse model of antibiotic-induced CDI, we confirmed that this strain is 
pathogenic.  Our serendipitous observations from this spontaneous outbreak of C. difficile 
in association with a pre- and peri-natal methyl-donor diet suggest the important role diet 
may play in host defense and CDI risk factors. 
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Importance 
Clostridium difficile infection (CDI) has become the leading cause of infectious 
diarrhea in hospitals worldwide, owing its preeminence to the emergence of 
hyperendemic strains, such as ribotype 027 (RT027).   A major CDI risk factor is 
antibiotic exposure which alters gut microbiota, resulting in the loss of colonization 
resistance.  Current murine models of CDI also depend on pretreatment of antibiotics of 
animals to establish disease.  The outbreak we report here is unique in that the CDI 
occurred in mice with no antibiotic exposure and is associated with a pre- and peri-natal 
methyl-supplementation donor diet intervention study.  Our investigation subsequently 
reveals that the outbreak strain we term 16N203 is an RT027 strain, and this isolated 
strain is also pathogenic in an established murine model of CDI (with antibiotics).  Our 
report of this spontaneous outbreak offers additional insight into the importance of 
environmental factors, such as diet, and CDI susceptibility.   
 
Introduction 
Clostridium difficile is a spore-forming, gram positive obligate anaerobe that has 
become the leading cause of infectious diarrhea in hospitals worldwide.  On a yearly 
basis, nearly half a million cases of Clostridium difficile infection (CDI) are reported in 
the United States (US), with an approximated 29,000 CDI-related deaths 172.  Exposure to 
C. difficile can have varied outcomes ranging from asymptomatic intestinal colonization, 
to severe diarrhea, development  of pseudomembranous colitis, and death 40. CDI risk is 
associated with disruption of the gut microbiota, for example following antibiotic 
administration 39–41, that leads to a loss of resistance towards C. difficile colonization.   
 
Following spore germination and establishment of the vegetative form of C. 
difficile, disease results from the production of the large clostridial toxins TcdA and TcdB 
173. These enterotoxins inactivate small GTPases 174–177 (e.g. Rho, Rac, Cdc42) and lead 
to the rearrangement of the actin cytoskeleton of intestinal epithelial cells.   
Consequently, mucosal epithelium damage ensues from cellular apoptosis 178 and the 
induction of colitis via toxin-mediated inflammation. In humans, the increasing clinical 
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presence of C. difficile epidemic strains in the US and West Europe 179 is attributed to 
antibiotic-use and the rise of endemic strains such as NAP1/027/BI. Ribotype 027 
(RT027) strains produce higher quantities of TcdA and TcdB 180 and express an 
additional C. difficile transferase (CDT) binary toxin encoded by cdtA/cdtB 181.  The 
binary toxin also disrupts the cytoskeleton and increases bacterial adhesion to intestinal 
epithelial cells 182.  The exact role of CDT in C. difficile virulence remains undefined, but 
it has been suggested that CDT plays a significant role in worsened clinical patient 
outcomes 183 and increases of CDI recurrence 184.   
 
Mouse models have been developed to study the pathogenesis of CDI. These 
models generally require administration of antibiotics to disrupt the microbiota prior to C. 
difficile exposure.  A number of antibiotic regimens have been employed to render 
animals susceptible to CDI 185–187.  The importance of the indigenous microbiota in 
mediating colonization resistance against CDI is highlighted by the fact that germ free 
animals are inherently sensitive to colonization and disease when exposed to C. difficile 
188.   
 
Here, we report a spontaneous outbreak of C. difficile due to a strain of RT027 
that occurred in a mouse colony that was associated with the administration of a specific 
pre- and peri-natal diet.  Given that CDI mouse models typically rely on prior gut 
microbiota disruption via antibiotics to establish disease 189, this outbreak is unique in 
that it occurred in the absence of antibiotic use and instead, in association with an altered 
diet. 
 
Materials and Methods 
Animals 
The animal care and use program at the University of Michigan is AAALAC-
accredited. All procedures involving the animals and their care were approved by the 
University of Michigan Institutional Animal Care and Use Committee. Mice were housed 
in autoclaved positive-pressure individually-ventilated cages (P/NV IVC, Allentown, 
Allentown, NJ) with corncob bedding (The Andersons, Frontier) and provided with 
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reverse osmosis-deionized (RO/DI) water through automated water systems (Edstrom; 
Waterford, WI). Animal housing rooms were maintained on a 12:12-h light:dark cycle, 
relative humidity of 30-70%, and temperature of 72 ± 2°F (22.2 ± 1.1°C). For specific-
pathogen free (SPF) rooms, cage changing and experimental procedures were performed 
under a laminar flow cage change station (AniGARD® VF, Baker Company, Sanford, 
ME) or in laminar flow benches, using a cold sterilant (Spor-Klenz®, Steris, St Loius, 
MO) for disinfecting gloved hands or transfer forceps.  For biocontainment rooms 
(animal biosafety level 2), procedures were performed under a biosafety cabinet 
(SterilGARD®, Baker Company, Sanford, ME) using a sporicidal disinfectant cleaner 
(Perisept, Triple S 48027).  Health surveillance program for SPF colonies included 
quarterly testing of dedicated soiled-bedding sentinel animals via fecal and perianal swab 
PCR or serology, and PCR of exhaust plenum swabs for fur mites. Health surveillance 
results indicated that the mice were negative for mouse rotavirus, mouse hepatitis virus, 
minute virus of mice, ectromelia virus, Theiler mouse encephalomyelitis virus, 
lymphocytic choriomeningitis virus, mouse adenovirus, mouse parvovirus, mouse 
polyoma virus, pneumonia virus of mice, reovirus, Sendai virus, Mycoplasma pulmonis, 
pinworms (Syphacia spp. and Aspicularis spp.) and fur mites (Myobia musculi, 
Myocoptes musculinis, and Radfordia affinis). 
 
Dietary Study 
In the initial dietary study, young adult (8 wk) C57Bl/6 mice were purchased from 
Jackson Laboratories.  All custom diets “TD” are produced and distributed by Harlan-
Teklad (Madison, WI).  Mice were acclimated for 2 weeks before feeding either control 
(TD.06689) or methyl-donor supplementation (MS) diet (TD.110144).  The MS diet 
contained 12g/kg methionine, 16.5 g/kg choline, 15 g/kg betaine, 16.5 mg/kg folic acid, 
1.56 mg/kg vitamin B12, and 200 mg/kg Zn. Two weeks after starting diet, female and 
male mice were paired for mating.  Mated F0 mice were fed the diet throughout 
pregnancy and lactation. F1 mice were weaned at 28 days.  The F1 mice were then placed 
on a standard chow diet (PicoLab Laboratory Rodent Diet 5L0D, LabDiet, St. Louis, 
MO) or a 42% high-fat diet (HFD) (TD.88137).   
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Outbreak necropsy and assessment 
Dead or clinically affected animals were detected during routine daily health 
checks. Veterinary staff assessed for any clinical sign of gastrointestinal or systemic 
disease, such as diarrhea, lethargy or unkempt appearance, and euthanized animals via 
CO2 inhalation followed by induction of bilateral pneumothorax. Complete necropsy was 
performed with select tissues processed for histologic examination.  
 
Fecal PCR of selected mice in the colony was performed by a commercial 
laboratory (Charles River Laboratories, Wilmington, MA) to confirm SPF status. Fecal 
and/or cecum and colonic samples were submitted for ELISA for C. perfringens type A 
toxin and C. difficile toxins A and B (Veterinary Diagnostic Laboratory, Michigan State 
University, Lansing, MI) or for real-time fluorogenic PCR for C. difficile targeting the 
23S rRNA gene (Charles River Laboratories, Wilmington, MA).  Cecum and colon 
tissues as well as tissues from other organs were fixed in 10% neutral buffered formalin 
for a minimum of 24 hours and then routinely processed to paraffin, sectioned, and 
stained with hematoxylin and eosin by the University of Michigan In Vivo Animal Core 
(IVAC) histology laboratory. A board-certified veterinary pathologist blinded to the diet 
groups evaluated the tissues descriptively in the initial outbreak and subsequently 
performed severity scoring of cecal and colonic tissues according to our previously 
published scoring system for experimentally-induced C. difficile-associated typhlitis and 
colitis 189. In brief, slides were evaluated on a 0-4 scale for the individual parameters of 
edema, inflammation, and epithelial damage and an overall severity score was generated 
by summing these parameters (scale 0-12). 
 
To investigate the outbreak source and the extent of contamination, environmental 
and fecal pellet PCR was performed as described above. Swabs were taken from various 
areas including cardboard rolls collected for mouse enrichment and the interior of the 
respective collection bins and supply and exhaust plenums of four autoclaved racks. 
Within the ABSL2 room, door knobs, biosafety cabinet used for changing cages, clean 
lixits, and rack supply ducts connected to the building ventilation system were sampled. 
Each PCR sample tested for the affected mouse colony comprised of pooled fecal pellets 
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(a fecal pellet collected from a representative mouse in each cage in each rack row) 
combined with the associated rack row’s exhaust plenum swab.  
 
C. difficile strain isolation, growth conditions, and colony identification   
C. difficile strain 16N203 was isolated from feces frozen at -80°C after collection 
from a spontaneously affected animal in the dietary study mouse colony.  1.5 fecal pellets 
were thawed, passed into an anaerobic chamber, and diluted in 200µL sterile anaerobic 
PBS.  20µL was placed into 3mL of taurocholate cefoxitin cycloserine fructose broth 
(TCCFB) and incubated at 37°C overnight.  A 10µL loop of the TCCFB enrichment 
culture was streaked onto taurocholate cefoxitin cycloserine fructose agar (TCCFA) to 
get an isolated colony of C. difficile.  The isolated colony was used for downstream 
applications.   
 
For colony identification, a 16N203 C. difficile colony was diluted in 15µL 
UltraPure Water (Invitrogen 10977-015), heated to 95°C for 20 min and then used for 
colony PCR to determine identity and toxin type of the isolated organism 190,191.  PCR 
was performed using the following primers for the C. difficile specific band F: 5’-
TTGAGCGATTTACTTCGGTAAAGA-3’ and R: 5’-
CCATCCTGTACTGGCTCACCT-3’ along with the universal 16S primers 515F: 5’-
GTGCCAGCMGCCGCGGTAA-3’ and E939R: 5’-
CTTGTGCGGGCCCCCGTCAATTC-3’ 190.  Toxin specific PCR followed previously 
published primers omitting the 16s rDNA primers 191.  The PCRs were run in a total 
volume of 25uL containing GoTaq Green Master Mix (Promega M712), primers, and 
nuclease free water. 
 
C. difficile cytotoxin assay   
Cytotoxicity assay was performed as previously described with the following 
modifications 189.  Briefly, ATCC CCL-81 Vero cells were grown to confluence in 
Dulbecco modified Eagle medium (Gibco 11965) supplemented with 10% fetal bovine 
serum (16140) and 1% Penicillin streptomycin (Gibco 15070).  Cells were plated to a 
density of 105 cells/well. Mouse cecal content was diluted 1:10 in sterile PBS, passed 
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through a 0.22µm filter, and serially diluted to 10-6.  Filtered samples were tested in 
duplicate with a corresponding control which both antitoxin (Techlab T5000) and sample 
were added.  A positive control of C. difficile TcdA (List Biologicals 152C) was used.  
Samples were incubated overnight at 37°C and the cytotoxic titer was determined as the 
reciprocal of the highest dilution that produced 80% cell rounding. 
 
Genome sequencing, variant identification, and comparative genomics 
A colony of C. difficile 16N203 was cultured 18 hours anaerobically at 37°C in 
13mL Brain Heart Infusion Broth (BD 211059) + 0.01% L-cysteine (Sigma C6852).  The 
culture was spun at 4500g for 12min, washed one time with sterile PBS, spun at 4500g 
for 12 min and the pellet was re-suspended in 300uL of Dneasy UltraClean Microbial kit 
Microbead solution (Qiagen 12224-50).  The extracted DNA was then prepared for 
sequencing on an Illumina MiSeq instrument using the NexteraXT kit and sample-
specific barcoding. Library preparation and sequencing were performed at the Center for 
Microbial Systems at the University of Michigan. Quality of reads was assessed with 
Fastqc 192, and Trimmomatic 193 was used for trimming adapter sequences and low 
quality bases. Genome assemblies were performed using Spades 194.  Variants were 
identified by: 1) mapping filtered reads to the assembled C. difficile strain 630 reference 
sequence (NC_009089.1) using the Burrows–Wheeler short-read aligner (BWA), 2) 
discarding PCR duplicates with Picard, and 3) calling variants with SAMtools and 
bcftools. Variants were filtered from raw results using GATK’s VariantFiltration (QUAL 
> 100, MQ > 50, > 10 reads supporting variant, FQ <0.025). In addition, a custom python 
script was used to filter out single nucleotide variants that were: 1) <5 bp in proximity to 
indels 2) <10 bp in proximity to another variant or 3) not present in the core genome.  
Maximum likelihood trees were constructed using core genome variants among the 
outbreak strain and a representative set of previously sequenced C. difficile genomes in 
FastTree 195.  MLST predictions were made by BLASTing genome assemblies against the 
PubMLST database for C. difficile (downloaded on January 3rd, 2017).  
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Experimental C. difficile infection  
8-wk old C57BL/6 wild-type (WT) mice (6 males and 3 females) were obtained 
from an in-house breeding colony that was established originally with animals from 
Jackson Laboratories (Bar Harbor, ME).  Mice were treated 10 days with 0.5g/L 
cefoperazone (MP Biomedicals 219969505) in sterile distilled water (Gibco 15230-147) 
as previously described 189. Briefly, animals were allowed to drink antibiotic amended 
water ad libitum and the antibiotic water was changed every other day.  After 10 days, 
antibiotic water was switched to sterile distilled water.  After 2 days on water without 
antibiotics, 3 male and 3 female mice (total treated n=6) were challenged via oral gavage 
with 500 spores of C. difficile strain 16N203. Spores (preparation described below) were 
suspended in 50µl Gibco sterile distilled water and 3 male mice (total mock n=3) were 
treated with 50µl of Gibco water only.   Mice were monitored 16 hours post infection and 
feces were collected and plated to confirm spore inoculation.  Mice were observed every 
3 hours for 36 hours for clinical signs of disease until clinical signs appeared.  Mice were 
euthanized by CO2 inhalation when clinical signs appeared or at study endpoint.  Mice 
were then evaluated at 48 hours after C. difficile infection for weight loss, activity, 
posture, coat, diarrhea and nose/eyes appearance 196.  Animals were euthanized and cecal 
contents and tissues from the animals were collected for culture and ELISA. 
 
C. difficile spore preparation 
16N203 was streaked onto TCCFA and an isolated colony was incubated 
overnight anaerobically at 37°C in 2mL Columbia broth (BD 294420).  The next day the 
culture was placed into 40mL of Clospore 197 and incubated anaerobically at 37°C for 8 
days.  The culture was spun at 3200rpm for 20min at 4°C.  The pellet was washed two 
times with sterile water (Gibco 15230-147), once with sterile 0.05% Tween 20 (Fisher 
BP337), and then once with sterile water.  The final pellet was resuspended in 1mL 
sterile water.  The spore stock was stored at 4°C in sterile water.  Prior to gavage, spores 
were heated to 65°C for 20min.  Spores were plated on TCCFA to determine dose 
administered to animals. 
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Results 
Recognition of an outbreak of severe typhlocolitis in a cohort of mice undergoing pre- 
and peri-natal diet manipulation 
Typhlocolitis was observed in a cohort of F1 mice from a study involving parental 
(F0) pre- and peri-natal methyl-donor supplementation (MS) and post-weaning intake of 
normal diet (ND) or 42% high-fat diet (HFD) chow. The purpose of the original study 
was to evaluate MS diet epigenetic effects on obesity development in later-life and at 
various life stages of the F1 mice.   
 
 
Figure 3-1 – Methyl-donor diet and advanced age mice had higher total mortality during 
outbreak. A) Epidemic curve depicting the first set of unconfirmed cases that triggered the 
outbreak investigation and the subsequent cases determined to be consistent with C. difficile 
infection. ^ - denotes environmental swab tests on 3/9/17, 3/15/17, 10/24/17 (not shown).  # - 
denotes plenum + fecal pellet testing on 4/14/17.  B) Kaplan-Meier survival curves of mouse 
colony comparing the percent survival of the pre-/peri- natal control diet (n=85) versus pre-/peri- 
natal methyl-supplementation diet (n=66) mice; F1 normal chow diet (n=101) versus 42% high 
fat diet (n=50) mice over the course of 8.5 months.  95% CI are graphed (gray dotted lines).  
* p<0.05, **** p<0.0001, Mantel-Cox log-rank test. 
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Over the course of 254 days from October 4th, 2016—June 15th, 2017, 57 out of 
207 mice in the MS diet study were found dead with no premonitory signs (n=39) or 
were euthanized for moribund condition (n=18), including hunched posture, lethargy, 
dyspnea, and mucoid stool with perineal staining. Severe necrotizing typhlocolitis with 
pseudomembrane formation and severe submucosal edema was observed at necropsy in 
early cases and was suggestive of C. difficile colitis 189. This led to screening of affected 
animals for C. difficile, which was subsequently identified in a number of these mice, 
suggesting a potential outbreak.  To facilitate investigation of this outbreak, we 
developed the following case definition: confirmed cases had 1) presentation of a 
compatible clinical syndrome and either, 2) histopathologic cecal/colonic lesions 
consistent with C. difficile infection or, 3) tested positive for C. difficile bacteria or C. 
difficile toxin.  Of the 57 animals that died during the study period, we were able to 
complete analysis on 36 mice and determined 25 of these mice fit our case definition.  
We excluded the 11 mice that were examined but found to have causes of death unrelated 
to the outbreak.  
 
We constructed an epidemic curve to follow the course of this outbreak. The 
initial 14 deaths in the colony that led to the outbreak investigation were included in this 
epidemic curve (Figure 3-1A), but as most of these animals were found dead, or 
intestinal tissue was not examined, case definitions could not be assigned to these mice.  
Over the course of the outbreak study, there were 86 MS diet and 97 control diet F1 mice.  
A Kaplan-Meier survival curve analysis on only the confirmed cases of CDI shows lower 
survival in the MS diet mice (n=66) compared to control diet mice (n=85) (Figure 3-1B).  
Curve analysis indicates that on day 254, which is the day on which the last outbreak case 
was identified, 96.5% of the control mice survived while only 66.7% of the MS mice 
remained (p < 0.0001).  A curve comparison of the confirmed CDI cases based on F1 
diets—HFD (n=50) versus ND (n=101) group suggests that HFD fed mice had higher 
survival percentages (p < 0.02), (Figure 3-1B); however, there were 65 F1 mice on HFD 
mice while 118 F1 mice were on ND in the initial colony.   
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To try and control this outbreak, breeders on the MS diet and control diet were 
transferred to a separate room in January 2017 based on negative fecal ELISA results. 
The remainder of the colony was ultimately transferred to containment housing. On 
4/14/17, PCR of pooled plenum and fecal pellets revealed 8/8 rows on one rack and 1/2 
rows on a second rack were positive for C. difficile. Environmental samples on 3 separate 
dates (3/9/17, 3/15/17, and 10/24/17) tested negative for C. difficile.  The timeline of the 
plenum swabs, fecal sampling, and environmental tests is also included on the epidemic 
curve (Figure 3-1A).   
 
 
 
Figure 3-2 – Necropsies and histopathology indicate typhlocolitis as primary diagnosis of 
affected animals.  A) Representative histology of mouse cecum in a C. difficile culture-positive 
case exhibiting severe submucosal edema and inflammation (arrow). H&E stain, Bar=200 µm.  
B) Representative histology of an area of cecum in the same case displaying mucosal necrosis 
(arrow) and extensive pseudomembrane formation (asterisk), consisting of neutrophils and 
sloughed enterocytes in a fibrinous matrix. H&E stain, Bar=100 µm. C) Histological severity 
scores for the 17 mice showing typhlocolitis, out of 24 clinically affected mice for which tissues 
were available. Severity was scored by a board-certified veterinary pathologist using an 
established murine C. difficile scoring system.  Each category—edema, inflammation, or 
epithelial damage was individually scored 0-4 and a summary score was generated (range 0-12). 
Of the 17 mice, 1 mouse had no cecum score and 1 mouse had no colon score due to tissue 
autolysis of those samples. As such, for cecum scores, control diet F1 mice n=3 and methyl-
supplementation diet (MS) F1 mice n= 13.  For colon scores, control diet n=2 and MS diet n=14.     
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Identification of C. difficile in animals with typhlocolitis    
Gastrointestinal (cecum and colon) tissues were available for histologic 
evaluation in 24 of the total 57 animals found dead or euthanized during the outbreak 
(Figure 3-2). 17 of 24 animals were found to have necrotizing and pseudomembranous 
typhlocolitis consistent with CDI as seen in experimental murine models 189. Histological 
findings included striking submucosal edema of the cecum and colon, accompanied by 
marked neutrophilic inflammation and necrosis and sloughing of the superficial to mid-
portions of the mucosa, often with pseudomembrane formation (Figure 3-2A-B). Of the 
17 animals with histologically evident typhlocolitis, we were also able to collect and 
submit fecal and/or cecum and colonic samples from 14 animals for testing.  12 of the 14 
animals tested positive for C. difficile TcdA and TcdB via ELISA and 2 tested positive 
for C. difficile bacteria via PCR. 14 were F1 mice from the MS diet and 3 were from the 
control diet groups (Figure 3-2C). The cecum summary scores (Figure 3-2C) in the MS 
diet (n=13) was 6.1 ± 2.6 and 9.3 ± 2.1 in the control diet (n=3).  The colon summary 
scores (Figure 3-2C) shows that MS diet (n=14) was 4.0 ± 2.2 and control diet (n=2) was 
4.5 ± 2.1. One MS-diet F1 mouse had missing colon scores and one control diet F1 
mouse had missing cecum scores due to tissue autolysis.  Given that significantly fewer 
control diet F1 mice (p<0.0001) were affected in the outbreak (Figure 3-1B), we 
collected fewer control samples and thus cannot draw conclusions on the effect of the F0 
diet on disease severity between the two groups of F1 mice.   
 
Overall, we observed that the histology score was higher in cecum than colon in 
most animals, consistent with experimental murine C. difficile models 189. Of the 
remaining 7 out of 24 histologically evaluated animals that did not have evidence of 
typhlocolitis, alternate causes of death/morbidity were identified, including tumors (n=2), 
bacterial enteritis (n=2), or undetermined by histology (n=3).  Finally, there were 12 out 
of 36 analyzed animals that had no gastrointestinal tissue available to be histologically 
evaluated, and 8 of these animals tested positive for C. difficile bacteria (n=2) and C. 
difficile toxins A and B (n=6) which then allows us to include these 8 as confirmed cases 
of C. difficile-related deaths.  The 4 animals that tested negative for C. difficile toxin were  
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Figure 3-3 – Isolation and genomic sequencing confirms NAP1/027/BI Clostridium 
difficile strain. A) Phylogenetic relationship between the mouse outbreak strain and 
representative C. difficile isolates. Isolates include publicly available clinical genomes, clinical 
isolates collected at the University of Michigan, and two mouse strains (16N203 and LEM1). A 
maximum likelihood tree was generated from the recombination filtered, polymorphic core 
genome positions in all isolates (N = 438). Clade 1 (purple) includes reference strain CD630 and 
mouse strain LEM1 (gray); clade 2 (red) includes epidemic RT 027. Clades 1-5 are as previously 
defined198–200. B) Tree in (A) was subset to include only 027 isolates. The mouse outbreak 
“16N203” strain (blue) clusters with the RT 027 isolates (pink), a RT in Clade 2 (red).   
 
found to have an alternative cause of death (endometritis n=1) or undetermined (n=3), 
and naturally, these were not included in the confirmed cases of C. difficile.   
 
Isolation of C. difficile was performed by the use of selective culture. A C. 
difficile strain (designated 16N203 for the animal from which it was initially isolated) 
was obtained in pure culture. A PCR 190 confirmed the C. difficile bacteria was present in 
fecal sample (Figure 3-5A), and this strain was also positive for the toxin genes 
tcdA/tcdB and cdtA/cdtB by PCR 191 (Figure 3-5B). Whole genome sequencing of strain 
16N203 was undertaken, and a whole genome phylogeny was constructed (Figure 3-3A), 
including a representative set of previously sequenced C. difficile isolates.  These isolates 
contain publicly available clinical genomes 198,201,202, clinical isolates collected at the 
University of Michigan, and two mouse strains (16N203 and LEM1).  LEM1 is an 
indigenous murine spore-forming C. difficile strain identified and isolated from mice 
acquired from common mouse vendors, Jackson Laboratories and Charles River 
Laboratories 203.  LEM1 appears to not be highly virulent and can protect against the 
closely related but more virulent strain VPI10463, at least in mice with C57BL/6J or 
Balb/c background 203.  In our data, the murine strain LEM1 clusters with Clade 1, which 
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contains reference strain CD630, while the outbreak strain fell within the diversity of 
Clade 2, which contains RT027 isolates (Figure 3-3A). When a phylogenetic tree was 
constructed with only RT027 isolates,  the outbreak 16N203 strain clustered with isolates 
derived from human patients with clinical CDI 204 (Figure 3-3B).   
 
C. difficile strain 16N203 is fully virulent in a mouse model of antibiotic-induced CDI  
We had previously demonstrated that C. difficile strains have variable virulence in 
an established mouse model where CDI susceptibility is conveyed by treatment with the 
antibiotic cefoperazone 189. To determine whether the pathogenicity of the outbreak strain 
16N203 was unique to the dietary model, we assessed whether the outbreak strain 
16N203 was virulent in this established model of CDI (Figure 3-4A). C57BL/6 mice on 
a standard diet and without previous dietary manipulations were treated with 
cefoperazone in drinking water for 10 days and then switched back to plain water.  Two 
days after stopping antibiotics, mice were challenged with either 500 spores of the 
16N203 outbreak strain or vehicle via oral gavage.  Significant weight loss (p<0.05) was 
observed in mice challenged with 16N203 spores during the 48-hour study time course 
while mock-treated mice maintained weight (Figure 3-4B). Mice challenged with C. 
difficile 16N203 had higher levels of cecal colonization (p<0.03) with detectable toxin in 
intestinal contents (p<0.05) and developed clinical signs compatible with severe CDI 
(Figure 3-4C).    
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Figure 3-4 – C. difficile ‘outbreak’ strain induces CDI in a standard mouse model 
with antibiotics. A) CDI mouse model with cefoperazone in drinking water used to assess 
virulence of the outbreak 16N203 strain.  Wild-type (WT) mice were administered cefoperazone 
in drinking water for 10 days on day -12 (D -12) and then orally gavaged either 16N203 spores 
(n=6) or the vehicle (distilled water) for mock (n=3) controls on day 0 (D0).   Mice were 
monitored for disease between D0 and D2.  B)  Body weight loss over the course of 48 hours; 
total percentage of body weight loss shown in column graph.  C)  Clinical score, colonization, 
and toxin scores at 48 hours.  For weight loss, clinical, colonization, and toxin scores, Mann-
Whitney test was used for statistical analyses, * p<0.05.  
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Figure 3-5 – PCR identification of Clostridium difficile and its associated toxins (TcdA, 
TcdB, and the binary cdtA/cdtB toxin)  A) PCR190 confirming C. difficile specific 
identification.  Lane 1 = 100bp ladder, Lane 2 = 16N203-1, Lane 3 = 16N203-2, Lane 4 = 
16N203-3, Lane 5 = 16N203-4, Lane 6 = C. difficile 630, Lane 7 = water.  B) PCR191 confirming 
presence of CDI toxins:  Toxin A (TcdA), Toxin B (TcdB), and binary toxin (cdtA/cdtB).  Lane 1 
= 100bp ladder, Lane 2 = 16N203-1, Lane 3 = 16N203-1, Lane 4 = 16N203-2, Lane 5 = 16N203-
3, Lane 6 = 16N203-4, Lane 7 = C. difficile R20291, Lane 8 = C. difficile 630. 
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Discussion 
In this report, we describe an outbreak of C. difficile infection (CDI) and colitis in 
laboratory mice associated with diet manipulation. This outbreak is interesting because 
spontaneous, symptomatic CDI is unusual in laboratory mice, and symptomatic colitis 
due to experimental CDI generally requires pretreatment with antibiotics 203,205. 
Subclinical colonization of mice has been reported previously. In one study it was noted 
that mice could be colonized with C. difficile with or without prior antibiotic treatment 
but this colonization was at a very low level and not associated with any clinical disease 
187. Administration of the antibiotic clindamycin was associated with increases in the 
levels of colonization but again without development of clinical colitis. It has been also 
reported that wild rodents can harbor toxigenic C. difficile strains, again without any 
overt disease 206.  
 
One group reported that laboratory mice obtained from multiple sources appear to 
harbor LEM1, an indigenous C. difficile strain 203. Colonization with LEM1 in the same 
study did not result in disease and in fact was associated with protection from disease 
following challenge with another strain of C. difficile that generally produces severe 
colitis in experimental models of CDI. In contrast, while LEM1 clusters with Clade 1 
(containing reference strain CD630 (RT 12)), the outbreak strain in our study clustered in 
Clade 2 with patient-derived RT 027 isolates and was associated with clinical disease in 
both spontaneously infected and experimentally infected mice. The source of this strain 
remains unclear, and our attempt at revealing a source with environmental sampling did 
not yield conclusive results. Ribotyping and genetic analyses suggest a potential source 
was through fomites or human carriers, but the source may have been gone by the time of 
environmental investigation.  
 
The mechanism underlying the unexpected increased susceptibility of these mice 
is also not entirely clear. Small animal models to recapitulate CDI pathogenesis generally 
rely on antibiotic pretreatment prior to experimental challenge with C. difficile, even with 
virulent strains 205. As noted, the current outbreak is unusual in that there were no 
antibiotics administered to the animals and instead susceptibility to colonization and 
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colitis was associated with dietary (peri- and pre-natal) manipulation. Our current 
understanding of the pathogenesis of CDI attributes loss of colonization resistance to 
altered structure and function of the indigenous intestinal microbiota 207. However, given 
the unexpected nature of the outbreak, we were not positioned to determine if there were 
changes in the microbiota associated to the increased susceptibility we observed in MS 
F1 mice.  Antibiotics, which can cause widespread changes in the indigenous microbiota, 
are associated with the development of clinical CDI in humans, but other factors that alter 
microbial populations may also convey susceptibility.  
 
In our study, increased C. difficile-associated deaths were seen in the offspring of 
mice receiving the methyl-supplementation (MS) diet.  Diet may be a factor that can alter 
the community structure and function of the intestinal microbiota, and diet-related 
susceptibility to CDI has been evaluated in some studies 44,208. Patients receiving enteral 
tube feeding had increased risk of developing CDI 209. Tube feeds given in the form of an 
elemental diet (i.e. a diet that is entirely absorbed within the small bowel) are thought to 
deprive the colonic bacteria of nutrition in the form of fiber and resistant starch, 
increasing the risk of CDI 210. Microbiota accessible starches may protect against CDI as 
in murine studies where feeding such carbohydrates can suppress experimental CDI 211. 
This protection was associated with an increase in short chain fatty acids which are the 
metabolic products of microbial fermentation of non-digestible carbohydrates. Another 
study showed that a low protein diet (which had reciprocal increases in carbohydrate 
composition) could be protective in a mouse model of CDI 212. In addition to 
macronutrients, it was recently demonstrated that zinc deficiency could alter the 
microbiota and increase susceptibility to experimental CDI 45.  
 
It should be noted that, in contrast to our study, the diet-related susceptibility or 
amelioration of experimental CDI discussed above occurred in models where the 
microbiota was still altered via antibiotic administration. An earlier study in hamsters fed 
an atherogenic diet in the absence of antibiotic administration, unexpected diarrhea and 
death due to colitis was observed in animals starting 45 days after diet manipulation 213. 
Similar to our study, toxigenic C. difficile was isolated from affected animals, although 
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typing of the strain was not performed. It is interesting to note that in these hamsters, the 
atherogenic diet increased susceptibility to CDI, but in our study, F1 mice that were on a 
42% high fat diet (HFD) exhibited increased survival—though it should be noted that this 
observation was limited by the fact that there were significantly more normal diet mice 
than HFD mice in the mouse colony at the time.  
 
While hamsters are exquisitely susceptible to C. difficile, symptomatic murine C. 
difficile colitis outbreaks in the absence of antibiotic administration are very rare. There is 
precedence for disease outbreaks in mice associated with C. difficile, but the affected 
mice have had significant immune alterations that increased their susceptibility 214,215. 
One such outbreak occurred in a murine experimental autoimmune encephalomyelitis 
model generated via the administration of pertussis toxin and a myelin oligodendrocyte 
glycoprotein fragment 215. These authors speculated that the stress of this experimental 
manipulation or the development of the autoimmune disease altered the microbiota in a 
manner that leads to susceptibility to CDI, but they did not profile the microbiota in these 
animals. Although we were unable to characterize the microbiota in our study due to the 
unexpected nature of the outbreak, a future avenue to explore would be diet-associated 
microbial community alterations that may convey susceptibility. 
 
Specific mechanisms by which our methyl-donor diet alters susceptibility to CDI 
are unclear.  A similar methyl-supplementation maternal diet was shown to increase 
colitis risk in a chemically-induced inflammatory bowel disease (IBD) using dextran 
sulfate sodium (DSS) 34,216. F1 mice from methyl-fed dams had worsened colitis and 
significantly higher mortality than control F1 mice 34.  Colonic mucosal bacterial 
diversity analyses indicated striking composition variation, including significantly higher 
prevalence of Clostridia in methyl diet F1 mice.  In addition, there was an increase in 
Firmicutes (Lachnospira, Oscillospira, Ruminococcus and Catonella) and a decrease in 
Parabacteroides and Eubacterium in methyl F1 mice compared to controls.  This 
suggests that dysbiosis between colitogenic (Firmicutes) and anti-inflammatory bacteria 
(Parabacteroides) following prenatal methyl supplementation may have led to the colitis 
prone phenotype 34. A fecal microbiome transfer (FMT) via cage swapping (between 
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methyl F1 mice and germ-free mice) was sufficient to worsen DSS-induced colitis in 
germ free mice, indicating that the maternal methyl-donor diet alone may enhance a 
colitis-prone microbiota profile.  While this study cannot be directly compared to C. 
difficile colitis, it strongly suggests that a prenatal methyl-donor diet is sufficient in 
generating a pro-colitic F1 microbiota. In the context of CDI, it remains to be determined 
whether susceptibility is due strictly to altered community composition, creating a niche 
for C. difficile colonization, or whether microbial changes directly promote colitis-
enhancing inflammatory responses. While unexpected, the current spontaneous outbreak 
of CDI in the absence of antibiotics in mice with parents fed an altered pre- and peri-natal 
diet may ultimately provide additional insight into the interplay of diet, host responses, 
and the microbiota that mediates CDI and colitis susceptibility. 
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Chapter 4 – Methyl-donor diet alters the murine gut microbiota but does not 
influence colonization resistance 
 
Manuscript in preparation. 
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Abstract 
Clostridium difficile infection (CDI) has become the most common nosocomial 
pathogen in North America and West Europe39–41.  CDI is typically associated to 
antibiotic-use, but cases of non-antibiotic associated CDI are similarly on the rise43.  
Recent studies have shown that diet plays a considerable role in the gut microbiome and 
its colonization resistance against CDI44,45.  In this current study, a methyl-
supplementation donor (MS) diet is administered as a pre- and peri-natal diet to 
C57BL6/J mice, and fecal sampling is performed before and throughout to map the 
changes that occur between F0 and F1 mice, before and after MS diet intake, and F1 mice 
microbiota community structure during CDI (using a murine outbreak strain ‘16N203’).  
We found the MS diet F1 mice have an increase in the relative abundance of 
Lactobacillus, Porphyromonadaceae and decreased abundance of Bacteroides, 
Akkermansia and Alistipes in F1 microbiota. These changes were not associated to a loss 
of CDI colonization resistance.  Additionally, our data indicate that the use of 
clindamycin erases the differences between control and methyl F1 diet mice, causing 
equivalent susceptibility to 16N203 C. difficile infection as assessed by    colonization 
and clinical scoring, gastrointestinal (cecum and colon) histopathology, and toxin 
quantification.   
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Introduction 
Clostridium difficile is a toxin-producing, spore-forming bacillus.  Clostridium 
difficile infection (CDI) has become one of the most frequent nosocomial infections, and 
it has dramatically increased its presence in both North America and West Europe over 
the past few decades217,218.  In humans, the major CDI risk factor is antibiotic-use which 
leads to the loss of colonization resistance, likely through its alteration of the gut 
microbiota. While the major risk factor for developing CDI in humans is still primarily 
antibiotic exposure, the rise of non-antibiotic associated CDI43 has led to studies on other 
environmental factors, including diet, that are also able to influence structure and 
function of the gut microbiota44,45.  
 
Dietary composition can also influence microbial community composition within 
the gut.  In human diet, a sugary substitute used in many processed foods, trehalose, has 
been shown to increase the fitness and virulence of the two major epidemic strains of C. 
difficile44.  In murine models of CDI, antibiotic pretreatment is typically required to 
induce susceptibility.  Even in an experiment that showed a high-zinc diet exacerbates 
CDI colitis in mice, antibiotic-exposure remained necessary for colonization and disease 
manifestation45.  Therefore, it was unexpected that an outbreak of C. difficile can occur in 
a mouse colony that uses no antibiotics and is only associated to dietary manipulation 
(unpublished, Chapter 3 under review).  We previously reported a spontaneous murine 
outbreak of 16N203 C. difficile, an RT027 strain, in F1 mice whose parents received pre- 
and peri-natal dietary manipulation.  This was interesting because mice without exposure 
to antibiotic pre-treatment typically do not become sick with CDI42,189,203,205.  Due to the 
spontaneous nature of the outbreak, diet effect on microbial communities could not be 
assessed in that outbreak study.   
 
The outbreak’s association to diet manipulation led us to speculate that the 
methyl-supplementation donor (MS) diet used in the study may play a role in CDI 
susceptibility.  Studies using mouse models have shown that early nutrition intervention 
rich in methyl-donors (L-methionine, folic acid, choline, betaine, zinc, and vitamin B-12) 
can influence F1 mice health in later life21,23–25,27,28,32,33.  The MS diet has been shown to 
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worsen chemically-induced dextran sulfate sodium (DSS) colitis in a mouse model of 
inflammatory bowel disease34,35.  Importantly, these studies show that the exacerbated 
outcomes of DSS-induced colitis can be achieved with a fecal microbiota transfer (FMT) 
between germ-free mice and MS diet F1 mice34. This suggests that early nutritional 
programming can influence the structure and possibly the function of the fecal microbiota 
in a way that conferred colitis susceptibility.    
 
To date, no studies have investigated changes in diet and its relationship to 
increased CDI susceptibility, without antibiotic exposure. We aim to investigate CDI 
susceptibility in F1 mice whose parents received pre- and peri-natal MS diet, without 
antibiotic exposure. We hypothesize that the MS diet leads to microbiota community 
structure changes that may increase CDI susceptibility in F1 mice. In this current study, 
we test the MS and control diets’ effect on fecal microbial community, and if so, whether 
these diet-induced changes associate with alterations to CDI susceptibility.  
 
Materials and Methods 
Animals and housing 
C57BL/6J 8-week old mice were purchased from Jackson Laboratories (Jackson 
West RB08; Sacramento, CA).  During the breeding and dietary intervention phase, all 
mice were housed under specific-pathogen free conditions in biosafety level 1 rooms 
maintained by the Unit for Laboratory Animal Medicine.  During the experimental 
infection phase, mice were transferred to animal biosafety level 2 rooms where 
procedures were performed under a biosafety cabinet using a sporicidal disinfectant 
cleaner (Perisept, Triple S 48027).  All procedures with animals and their care are 
approved by the University of Michigan Institutional Animal Care and Use Committee.   
 
F0 mice dietary protocol 
C57BL/6J 8-week old female and male mice were placed on custom “TD” diets 
produced and distributed by Harlan-Teklad (Madison, WI).  Mice were acclimated for 2 
weeks upon arrival and then placed on either control (TD.06689) or methyl-donor 
supplementation (MS) diet (TD.110144) for 2 weeks.  Mice were then paired for mating 
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and fed the diet throughout pregnancy and lactation.  As previously described33, the MS 
diet (TD.110144) is comprised of 12g/kg methionine, 16.5 g/kg choline, 15 g/kg betaine, 
16.5 mg/kg folic acid, 1.56 mg/kg vitamin B12, and 200 mg/kg Zn.  The MS diet has 
18.8% protein, 62.1% carbohydrate, and 19.1% fat (% kcal from).  The control diet 
(TD.06689) is comprised of 4.3 g/kg methionine, 1.35 g/kg choline, 0 g/kg betaine, 0.003 
mg/kg folic acid, 0.06 mg/kg vitamin B12, and 0.05 mg/kg Zn.  The control diet has 
17.6% protein, 64.0% carbohydrate, and 18.4% fat (% kcal from).  F1 mice were weaned 
at 28 days and then placed onto a standard chow diet (PicoLab Laboratory Rodent Diet 
5L0D, LabDiet, St. Louis, MO).   
 
Fecal microbiome sample collection 
Fresh fecal microbiome samples (MBS) were collected from each F0 mouse prior 
to diet-exposure, prior to pairing for mating, and twice after paired.  MBS was also 
collected from F1 mice beginning at post-weaning until 3 months of age.  All MBS prior 
to spore-gavage were collected fresh and snap frozen in liquid nitrogen in twist-cap tubes.  
MBS were also similarly collected throughout experimental-infection phase.   
 
Isolation of lymphocytes and cell counting 
Peyer’s patches (PP) and mesenteric lymph nodes (mes LN) were excised, 
collected through a 70 µm filter, and washed with ice cold buffer (5% fetal bovine serum 
(FBS), 0.4% EDTA in PBS) prior to centrifugation (3000 RPM, 5 min.) to form a cell 
pellet.  The supernatant was discarded and RBC depletion was performed with ACK 
(Lonza, #10-548E) and washed through a 70 µm filter to neutralize ACK.  After rinse and 
resuspension in cold sterile PBS buffer, 10 µl aliquots of each sample was used for a cell 
count using Trypan blue paired with an automated cell counter (Invitrogen Countess 
1754B).   
 
T cell cytokine stimulation 
PP and mes LN cells were cultured in 6-well plates for 4 hours at 36°C in a 5% 
CO2 incubator in T-cell media (RPMI medium supplemented with 1% penicillin and 
streptomycin, 1% L-glutamine, 10µM β-mercaptoethanol and 5% heat-inactivated FBS) 
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in the presence of Monensin (Biolegend 420701) and Cell Activation Cocktail 
(Biolegend 423303) containing phorbol 12-myristate-13-acetate (PMA), ionomycin, and 
Brefeldin A.  Treatment concentrations were used as per manufacturer suggestions.  At 4 
hours, cells were gently removed with pipette and washed with PBS and spun down to 
form cell pellet.   
 
Flow cytometry staining 
Single cell suspensions of PP and mes LN were resuspended in PBS in conical 
pyrostyrene tubes.  Small cell samples from each mouse are pooled to form control cells 
for single positive controls (SPCs), full-minus-one controls (FMOs), and the unstained 
cells.  Sample cells were stained for 30 min (on ice and in the dark, for all stain steps) 
with a Live/Dead Fixable Dead Cell Stain Kit (Invitrogen L34959).  Cells were blocked 
for 1 hr on ice with anti-mouse CD16/CD32 Purified (eBioscience Affymetrix #14-0161).  
Following 2 cold PBS rinses, cells were stained with surface markers, anti-mouse CD3 
Percp-eF710 (eBioscience 46-0033-80), CD4 PeCy7 (eBioscience 25-0041-81), and CD8 
FITC (eBioscience 11-0081) for 45 min.   Following 2 washes, the cells were processed 
with a Fix/Perm Intracellular Staining Buffer Set (eBioscience 00-5523) and then stained 
with a master mix containing intracellular markers anti-mouse IL-17 APC-Cy7 (BD 
Pharmingen 560821), IL-22 APC (eBioscience 17-7222-80), Foxp3 PE (eBioscience 12-
4774), IL-10 V450 (BD Horizon 561429), and IFN-γ Alexa 700 (557998) for 45 min.  
Cells were washed and maintained in sterile-flitered FACS buffer (PBS, 0.5% BSA and 
0.1% NaN3) until flow cytometry analysis was performed on a LSR Fortessa (University 
of Michigan Flow Cytometry Core) and analyzed on FlowJo v. 10.2.   
 
Genomic DNA extraction, amplification and sequencing  
For microbial community analysis, the V4 region of the 16S rRNA gene was 
sequenced. Genomic DNA was extracted from fecal pellets using a PowerMagSoil DNA 
isolation Kit (Mo Bio Laboratories, Inc) using an epMotion 5075 liquid handling system 
(Eppendorf). The V4 region of the 16S rRNA gene was PCR-amplified prior to 
sequencing using a MiSeq (Illumina) sequencer as previously described219,220.   
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Sequence processing and analysis 
16S rRNA gene sequences were analyzed using mothur (v.1.39.5) and MiSeq 
SOP (accessed January 2018)219,221.  Sequences aligned to the SILVA reference database 
were organized into operational taxonomic units (OTUs) at a 97% sequence similarity 
using the OptiClust algorithm222–224. To compare fecal community composition between 
control and MS diet F1 mice, relative abundances of the highest abundance OTUs (>1% 
of all sequences) were visualized using the R package “pheatmap” (https://cran.r-
project.org/web/packages/pheatmap/index.html) and clustered using an Euclidian 
algorithm. To determine similarities between different samples, θYC distances were 
calculated using mothur followed by an analysis of similarity (ANOSIM). A biplot was 
generated to determine which OTUs explained the variance of the community structure 
between diet groups using significantly correlated OTUs to principle coordinate axes 1 
and 2. This was calculated using a Spearman correlation (P< 0.001). 
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Results 
 
 
 
 
Figure 4-1 – Dietary protocol, microbiota sample collection, and infection model.   
A) Dietary protocol and fecal sample collection in F0 and F1 mice.  Methyl-donor 
supplementation (MS) diet (yellow) and control diet (blue) F0 mice were paired and post-
weaning, F1 from each group were placed on normal chow diet (brown).  B) Infection model with 
no antibiotic use. Control and MS diet F1 mice were partitioned into either mock-treated or 
16N203 C. difficile infection groups and gavaged on D0 with PBS or 104 16N203 C. difficile 
spores.  C) Infection model in “B” with an IP-injection of 10mg/ml clindamycin on D9 in all 
mice followed by an additional gavage of 104 spores on D10 to C. difficile-infection group and 
PBS to mock controls. 
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Fecal samples were collected from both F0 and F1 mice to test for diet effects on 
fecal microbiota composition.  In F0 mice, fecal samples were collected before and after 
pre- and peri-natal diet administration for both control and methyl-donor supplementation 
(MS) diet (Figure 4-1A).  In F1 mice, fecal samples were collected at 1- and 2-months of 
age prior to experimental C. difficile infection (CDI).  Throughout the infection phase, 
fecal samples were collected and on day 12 (D12), colonic and cecal contents were also 
collected at time of tissue harvest.   
 
At 3-months of age, the F1 mice are gavaged with 16N203 C. difficile 104 spores 
or PBS on D0 (Figure 4-1B, Figure 4-1C) and monitored for signs of clinical 
presentation of CDI.  To determine MS diet effects on F1 microbial community structure, 
the richest abundances (>1% of all sequences) of operational taxonomic units (OTUs) in 
F1 fecal microbiota samples (uninfected) are determined with our 16S rRNA gene 
sequencing results clustered at 97% sequence similarity (Figure 4-2).    
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Figure 4-2 – Parental methyl donor diet intervention alters the gut microbiota in F1 mice.  
A) Relative abundances of the most abundant operational taxonomic units (OTUs) (>1% of all 
sequences) from fecal samples taken from F1 mice whose parents received the control diet (blue 
boxes) or methyl-supplementation (MS) donor diet (white boxes). Samples were clustered based 
on the Euclidian algorithm using the R package “pheatmap”. B) Biplot representing community 
structure comparison of feces from control (teal) and MS diet (magenta) F1 mice. Principal 
coordinate analysis was based off of theta similarity (θYC). Arrows indicate OTUs that are 
significantly correlated with axes 1 and 2, and these were calculated using Spearman correlation 
(P<0.001).  Data generated by Josie Libertucci from Young Lab. 
 
Compared to control diet F1 mice, the MS diet F1 mice distinctly associate with 
different abundances of phyla in the fecal microbiota community structure (Figure 4-
2A).  We show that sequence similarity cluster F1 mice into distinct groups of control 
and MS diet, indicating that OTUs’ abundances are distinctly different with the use of a 
MS diet.  To identify similarities and dissimilarities associated with the pre- and peri-
natal control diet versus methyl diet on F1 microbiota community, a biplot was generated 
via principal coordinate analysis based on theta similarity (θYC) (Figure 4-2B).  The 
control diet is associated with enriched relative abundances of Akkermansia, Alistipes, 
Lachnospiraceae, and Acetatifactor.  In contrast, the MS diet is associated with higher 
relative abundances of Lactobacillus, Porphyromonadaceae, and Pseudoflavonifractor.  
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Figure 4-3 – Microbiota changes in MS diet F1 mice do not associate with changes to CDI 
susceptibility.  Weight changes post-gavage with 104 spores or PBS in F1 mice and colonization 
detection in A) control diet mock-treated mice, B) control diet 16N203 C. difficile infected mice, 
C) methyl diet mock-treated mice, and D) methyl diet 16N203 C. difficile infected mice. The 
Kruskal-Wallis test was used to assess statistical significance, * p<0.05, ** p<0.01, *** p<0.001, 
**** p<0.0001.  Data from this figure generated by Kim Vendrov and Josie Libertucci from 
Young Lab.   
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Interestingly, the microbiota community changes noted (Figure 4-2) in MS diet 
F1 mice (uninfected) do not associate with alterations to CDI susceptibility (Figure 4-3).  
When mice were challenged with 16N203 C. difficile with no pretreatment of antibiotics 
(Figure 4-1B), they do not become colonized nor develop observable symptom (weight 
loss) of CDI (Figure 4-3A-C).  With exception, a single MS diet F1 mice mouse appear 
to become colonized by D3 and remain colonized on D7 (Figure 4-3D).  However, this 
individual mouse does not lose body weight (Figure 4-3D) nor develop other clinical 
presentations (not shown) of CDI, it may have been an asymptomatic carrier.   
 
In a separate cohort of mice, we use a standard dose of clindamycin pretreatment 
prior to a re-gavage with 16N203 spores (Figure 4-1C), we observe colonization and 
clinical presentation of CDI (Figure 4-4).  On D11, fecal samples were collected and 
streaked on C. difficile-enrichment plates to determine colonization status of F1 mice.  As 
expected, mock-treated control and MS diet F1 mice remain uncolonized, and 16N203 C. 
difficile exposed mice of both diets become highly colonized by D11 (Figure 4-4A).  
Interestingly, a subset of control diet F1 mice appears to have lower colonization than 
MS diet F1 mice.  By D12, cecal contents are cultured to measure colonization, and both 
diet F1 groups were highly colonized (Figure 4-4A).   
 
Clinical scores are assessed according to a previously established C. difficile 
infection (CDI) scoring system196.  Briefly, the total clinical score of each animal is 
cumulative of 6 parameters including activity, posture, coat, diarrhea, eyes/nose, and 
weight loss scores.  Mock-treated animals were free of colonization and exhibited no 
observable clinical phenotypes (Figure 4-4B).  Whereas, 16N203 C. difficile infected 
mice of both diets are highly colonized, and control and MS diet mice both display CDI 
clinical phenotypes.  Activity and posture scores are increased in MS diet mice (p<0.001 
and p<0.01), total clinical scores between the two diet groups indicated no significant 
difference (Figure 4-4B).   
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Figure 4-4 – 16N203 ‘outbreak’ strain is pathogenic in both control and methyl F1 mice.   
A) Colonization scores in pre- and peri-natal control (open circles) and MS diet (filled circles) F1 
mice on day 11 in fecal samples and on day 12 from the cecum are shown on a logarithmic scale.  
B) Total clinical scores shown are cumulative of activity, posture, diarrhea, weight loss, coat, and 
eyes/nose scores on day 12.  n=12-14 per diet/infection group. The Kruskal-Wallis test was used 
to assess statistical significance, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.  Data from 
this figure generated by Kim Vendrov and Josie Libertucci from Young Lab.   
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At D12, animals were sacrificed and gastrointestinal (cecum and colon) tissues 
are collected for histological evaluation (Figure 4-5).  Histological assessment of the 
cecum (Figure 4-5A-D) and colon (Figure 4-6A-D) indicate that 16N203 C. difficile led 
to evident submucosal edema and mucosal damage with sloughed epithelium and 
neutrophilic inflammation, consistent with other murine experimental C. difficile strains 
and similar to what was observed in the spontaneous outbreak from which the 16N203 
strain was derived (Chapter 3).  The cecum and colon summary scores were cumulative 
of edema, epithelial, and inflammation scores as previously described.  Based on cecum 
and colon summary scores (Figure 4-5E), MS diet and control diet mice have similar 
CDI severity.  
 
Figure 4-5 – Histopathology in the colon and cecum of 16N203 C. difficile-infected F1 mice. 
Representative histological images of cecum depict A) control diet/mock, B) control 
diet/16N203-infected, C) methyl diet/mock, and D) methyl diet/16N203-infected. Hematoxylin 
and eosin staining. Scale bars 200 µm (insets 20 µm).  n=12-14 per diet/infection group. 16N203 
C. difficile infected animals had submucosal edema (arrows) and mucosal damage (asterisks) 
consisting of sloughed epithelium and neutrophilic inflammation. E) Colon and cecum summary 
scores are cumulative of edema, inflammation, and epithelial scores, ranging from 0-4 per 
category, max=12.  Ingrid Bergin, a board-certified histopathologist scored these. Kruskal-Wallis 
test, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.   
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Figure 4-6 – Colon histopathology in MS diet and control diet F1 mice.  
Representative histological images depict A) control diet/mock, B) control diet/16N203-infected, 
C) methyl diet/mock, and D) methyl diet/16N203-infected.  16N203 C. difficile infected animals 
had submucosal edema (arrows) and mucosal damage (asterisks) consisting of sloughed 
epithelium and neutrophilic inflammation. Insets depict higher magnification of mucosal surface. 
Hematoxylin and eosin staining. Scale bars 200 µm (insets 20 µm).  Histopathology was assessed 
with n=12-14 per diet/infection group. Kruskal-Wallis test, * p<0.05, ** p<0.01, *** p<0.001, 
**** p<0.0001.  Ingrid Bergin, a board-certified histopathologist scored these.  
 
On D12, we also collect and perform flow cytometry analysis on total cells in the 
mesenteric lymph nodes (mes LN) and Peyer’s patches (PP). We find that mock-treated 
MS diet F1 mice have higher total mes LN cells than control diet F1 mice (p<0.05) 
(Figure 4-8A).  16N203-infected MS diet F1 mice had higher total PP cells than controls 
(p<0.05) (not shown).  We observe no differences in total CD3+ T cells in the mes LN, 
and there was a modest increase in the CD4:CD8 T cells in MS diet F1 mice when 
infected with 16N203 (p<0.05) (Figure 4-8B).  Intracellular staining for CD4+ and 
CD8+ T cell cytokine expression of IL-10, IL-22, IL-17, and IFN-γ indicated no 
differences at D12, 36 hours post-infection within the mes LN (Figure 4-8C).  We 
observe a small decrease in CD8+ Foxp3+ cells (p<0.05) with no changes in IL-10 
expression (not shown).  We find that mock controls and 16N203 animals had little 
difference—D12 (48 hours) may be too late of a timepoint for CDI immunological 
profiling in the mes LN.   
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Figure 4-7 – MS diet F1 mice express higher CD4+:CD8+ T cell ratio during C. difficile 
infection.  A)  Total cell counts from mesenteric lymph nodes (mes LN) and total CD3+ T cells 
are shown between control diet and MS diet F1 mice that were either mock treated or infected 
with 16N203 C. difficile.  B) Flow cytometry representative panel is gated on singlets > CD3+ > 
CD4+ (y-axis) and CD8+ (x-axis).  Frequency of CD3+ cells are shown as a percentage of total 
singlets, CD4+ T and CD8+ T cells are shown as percentages of total CD3+ T cells. T cell ratio 
between CD4:CD8 is shown.  C) Mesenteric lymph node cytokine expression of IL-10+, IL-22+, 
IL-17+, and IFN-γ+ were measured in CD3+CD4+ and CD3+CD8+ T cells.  Error bars are SEM.  
Flow cytometry experiments contain n= 12-14 per diet/infection group. 
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A) 
 
B) 
 
Figure 4-8 – Clindamycin flattens fecal and cecal microbiota community structure 
differences between control and MS diet F1 mice.  Biplots representing community structure 
comparison of control (red) and MS diet (blue) F1 mice A) fecal contents on D10 post-IP 
clindamycin and B) cecal contents on D12 at the time of harvest. n=12-14 per diet/infection 
group. Principal coordinate analysis was based off of theta similarity (θYC). OTUs that are 
significantly correlated with axes 1 and 2 were calculated using Spearman correlation (P<0.001).  
Data generated by Josie Libertucci from Young Lab. 
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To determine how clindamycin may have altered fecal and cecal microbiota 
community structure in control and MS diet F1 mice, we compare the two diet groups on 
D10 (fecal) and D12 (cecal) (Figure 4-7).  On D10, post-clindamycin injection and prior 
to re-gavage with 16N203 spores, a PCA indicates that clindamycin rendered both the 
fecal microbiota community structures in control and MS diet F1 mice to look similar.  A 
second biplot was generated to compare cecal microbiota community structure between 
the two F1 diet groups on D12, showing that both F1 diet groups are not distinct from one 
another.  Based on these data, we conclude the clindamycin pretreatment’s effects on F1 
diet mice fecal/cecal microbiota may contribute to the similarities observed in the CDI 
clinical, immunological, and histopathological outcomes between the two groups. 
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Discussion 
Our data show the pre- and peri-natal methyl-supplementation donor (MS) diet 
administered to F0 C57BL/6 mice significantly alters F1 mice fecal microbiota 
community.  The major changes we found in the MS diet F1 mice are the increases in 
Lactobacillus and Porphyromonadaceae and decreases in abundance of Bacteroides, 
Akkermansia and Alistipes compared to control mice. Interestingly, when challenged with 
the 16N203 C. difficile strain, MS diet F1 mice did not become colonized (with exception 
to 1 mouse that was asymptomatic).  Additionally, our data indicate that the use of 
clindamycin erases the differences between control and methyl F1 diet mice, leading to 
similar susceptibility and severity towards 16N203 C. difficile as assessed by    
colonization and clinical scoring, gastrointestinal (cecum and colon) histopathology, and 
toxin quantification.   
 
Alteration of the gut microbiota, leading to dysbiosis, is a major contributing 
factor to Clostridium difficile infection (CDI) susceptibility.  As such, CDI typically 
occurs following multiple exposures to antibiotics, resulting in a disruption of the 
microbial community within the gut and therefore loss of colonization resistance225,226.  
Other environmental factors may also alter C. difficile susceptibility.  Diet is among the 
environmental factors that influence CDI susceptibility.  A recent report demonstrated 
that trehalose, a sugar present in many processed foods for humans and livestock, may 
have ignited the epidemic spread of C. difficile RT027 strains in North America44.   In 
mice, excess zinc in diet alone can cause alterations to the microbiota and decrease the 
amount of antibiotic pretreatment to exacerbate experimental CDI45.   
 
Early nutrition in the form of pre- and peri- natal diet has been demonstrated to 
affect later life disease susceptibility in offspring27, as such the potential impact of diet 
and CDI susceptibility is important to explore.  For example, pre- and peri-natal methyl-
supplementation (MS) diet use has been shown to alter F1 mice fecal microbiota 
community in such a way that exacerbates chemically-induced colitis 34,35.  This study 
concludes that the MS diet led to a pro-colitic microbiota, in particular, there was 
significantly higher abundance of Clostridia and Firmicutes accompanied by decreases in 
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Parabacteriodes and Eubacterium.  In the same study, cage-swapping experiments for a 
fecal microbiome transfer (FMT) between MS diet, control diet, and germ-free mice was 
sufficient to worsen colitis in the mice that were exposed to MS diet fecal microbiota34,35.   
These studies did not venture into whether the microbial changes were associated with 
any immune responses.   
 
The MS diet has been shown to affect immune responses (T cells) in an 
atherosclerosis mouse model32,33.  In the current study, the modest increases to the 
CD4:CD8 T cell ratio in the mesenteric LNs of infected MS diet F1 mice were 
accompanied by no changes to CD4+ and CD8+ cytokine expression of IL-10, IL-22, IL-
17, and IFN-γ.  We postulate that two limitations may be the time point at which these 
immunological changes were assessed and the administration of clindamycin.  At D12, 
36-hours post-infection, mice infected with C. difficile had severe damage and alterations 
to gut structure and function as indicated by histopathology (and toxin levels).  Given this 
context, mesenteric LNs and Peyer’s patches T cells among other immune cells may be 
similarly aberrant and accurate measures of these cells difficult.   
 
Our current study indicates that early-life diet intervention in the form of a pre- 
and peri-natal methyl-supplementation donor diet can alter the F1 microbial community 
structure. Changes in progeny microbiota is sustained rather than transient as community 
structure was evaluated in sexually mature adult mice. When challenged with 16N203 C. 
difficile prior to and following antibiotic administration, these changes in community 
structure did not result in altered colonization resistance nor clinical outcomes compared 
to control diet F1 mice.  16N203 is a ribotype 027 (RT027) C. difficile strain isolated 
from a spontaneous outbreak in a mouse colony that was associated with the 
administration of the MS pre- and peri-natal diet.  During the outbreak, MS diet F1 mice 
succumbed to CDI at significantly higher numbers than control diet F1 mice (Chapter 3).  
Standard CDI mouse models rely on antibiotic disruption of the microbiota to enable 
colonization and disease.  We postulated the MS diet alters F1 mice microbiota and 
possibly gut immune responses, and these changes, if true, may explain increased 
susceptibility in the outbreak.   
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In this current study, under experimental exposure of the 16N203 C. difficile 
strain to control and MS diet F1 mice, we found that parental diet does alter F1 
microbiota.  However, at the dosages we tested, 16N203 C. difficile did not colonize MS 
and control diet F1 mice until a dose of clindamycin was administered.  The 
concentration of clindamycin that was used (10mg/ml) enabled CDI in this study but not 
a previous study42.  In this study, clindamycin administration essentially led to a 
flattening of the microbiota diversity and erased differences between control and MS diet 
mice.  Unsurprisingly, this led to very similar clinical outcomes in both diet groups.  If a 
reduced concentration was used, this could have better tested microbial alterations that 
may have led to the differing CDI severity between control and MS diet F1 mice reported 
in the outbreak.   
 
Our study was limited in that the clindamycin prescribed in infection model B 
was sufficient to enable colonization and disease which is not the case in a different study 
using the same strain.  However, this parallels many recent studies227–230 that show the 
microbiotas between colonies of the same strain of mice are different from various 
vendors can severely affect reproducibility.  We postulate that it is also possible that the 
outbreak of 16N203 C. difficile in the mouse colony were mice from a different vendor-
barrier, the microbiota of those mice may have interacted differently with the diet 
manipulation than the mice in this current study.  These results provide support for 
continuing investigation of the relationship between parental diet intervention and 
susceptibility to C. difficile infection in offspring.  Very little is known regarding the 
interactions between C. difficile and dietary alterations, microbiota composition, and host 
responses.  Improved knowledge of how dietary factors influence gut microbiota 
structure and function could lead to a better understanding of C. difficile pathogenesis and 
may create potential for diet-based prevention strategies.   
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Chapter 5 – Methyl-donor supplementation diet does not protect C57BL/6J F1 mice 
from later-life diet-induced obesity 
 
Abstract 
Early-life nutritional programming influences late-life disease susceptibility 
across generations1,2,19, in part through epigenetic mechanisms including DNA 
methylation. It has been shown that pre- and peri-natal diet rich in methyl-donor 
supplements (L-methionine, vitamin B-12, folic acid, choline, betaine, zinc) can protect 
the agouti viable yellow (Avy) mouse from obesity18 and cancer24.  In other mouse models, 
this methyl-donor supplementation (MS) diet affect F1 host responses to disease in 
different ways34,35,231.  We have previously shown the MS diet reduces T-cell mediated 
inflammation in a mouse model of spontaneous atherosclerosis32,33.  In the same study, 
we noted that MS diet F1 C57BL/6J mice were born smaller and maintain these leaner 
body sizes into adulthood33.  Here, we hypothesize the MS diet may resist the harmful 
effects of diet-induced obesity in F1 C57BL/6J mice through suppression and reduction 
of adipose tissue inflammation. Our results suggest that the MS diet does not alter obesity 
nor metabolic inflammation outcomes we measured in C57BL/6J F1 mice. 
 
Introduction 
The immune system develops extensively in utero232–236, and maternal-fetal 
interactions are important for determination of immunity and tolerance237,238.  As early as 
the 2nd trimester, the developing fetus gains a functional immune system that differs from 
adult immune system239.  It has been shown that altering the developmental environment 
with maternal pre- and peri-natal methyl-donor diets can influence the establishment of 
epigenetic states during tissue differentiation in a developing fetus20,23,25,240.  Methyl-
donor diets influence the methylation process by enhancing the S-adenosylmethionine 
(SAM) pool which is an intermediate product of methionine metabolism17.   
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In humans, folic acid supplementation has been used (since mid-1970s) to prevent 
fetal neural tube defects which are believed to partially occur due to insufficient 
methylation during development241.  Methyl-donor supplements that have been used in 
mouse studies as a pre- or peri- natal diet typically include combinations of folate, 
choline, betaine, and vitamin B1227.   The methyl-donor supplementation (MS) diet 
protects agouti viable yellow (Avy) mouse offspring from developing obesity and tumors, 
thereby also extending their lifespan18,23,24.  This is a classic demonstration of non-
genomic inheritance of epigenetic marks and of early-diet’s capacity to inflict later-life 
health outcomes.  However, agouti viable yellow (Avy) mice spontaneously develop 
obesity and tumors as a result of ectopically expressing agouti due to a retrotransposon 
insertion25.  Therefore, it is important to determine whether these benefits of the MS diet 
are unique to the agouti viable yellow (Avy) mice or useful beyond this model.  
 
In our previous studies using the MS diet, we observed that compared to the 
control diet, MS diet F1 C57BL/6J mice were born smaller and maintain these leaner 
bodies into young adulthood33.  C57BL/6J mice do not spontaneously develop obesity 
like the agouti viable yellow (Avy) mice.  Therefore, to test if the MS diet can protect 
C57BL/6J F1 mice from obesity, in this study, we challenged control and MS diet F1 
mice with a normal diet (ND) or a 42% high fat diet (HFD).  In order to determine if the 
MS diet protects F1 mice from obesity and diet-induced metabolic dysfunction, we assess 
adipose tissue inflammation in the gonadal white adipose tissue (WAT).   
 
Inflammation in diet-induced obesity (DIO) is termed ‘metaflammation.’ It is a 
chronic, low-grade inflammation that has been attributed as the inflammatory 
pathogenesis of diet-induced metabolic dysfunction242.  Adipose tissue inflammation is 
an especially crucial driver of metaflammation given the capacity and penchant of 
adipocyte and adipose tissue resident immune cells’ secretion of pro-inflammatory 
mediators51,59–61,63–66,69,70,75,77 during obesity.  In particular, tumor necrosis factor-α 
(TNFα) produced by adipose tissue macrophages (ATMs) during metaflammation has 
been demonstrated to interfere and block insulin signaling, revealing part of the 
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molecular mechanism to insulin resistance51.  ATMs in obese adipose tissue have been 
considered a major player in adipose tissue inflammation, as they are major constituents 
in the tissue and have shown to phenotypically ‘switch’ towards pro-inflammatory M1-
polarized ATMs in DIO mouse models60,61.   
 
Materials and Methods 
Animals and housing 
C57BL/6J 8-week old mice were purchased from Jackson Laboratories (Jackson West 
RB08; Sacramento, CA).  During the breeding and dietary intervention phase, all mice 
were housed under specific-pathogen free conditions in biosafety level 1 rooms 
maintained by the Unit for Laboratory Animal Medicine.  During the experimental 
infection phase, mice were transferred to animal biosafety level 2 rooms where 
procedures were performed under a biosafety cabinet using a sporicidal disinfectant 
cleaner (Perisept, Triple S 48027).  All procedures with animals and their care are 
approved by the University of Michigan Institutional Animal Care and Use Committee.   
 
Dietary Study 
In the initial dietary study, young adult (8 wk) C57Bl/6 mice were purchased from 
Jackson Laboratories.  All custom diets “TD” are produced and distributed by Harlan-
Teklad (Madison, WI).  Mice were acclimated for 2 weeks before feeding either control 
(TD.06689) or methyl-donor supplementation (MS) diet (TD.110144).  The MS diet 
contained 12g/kg methionine, 16.5 g/kg choline, 15 g/kg betaine, 16.5 mg/kg folic acid, 
1.56 mg/kg vitamin B12, and 200 mg/kg Zn. Two weeks after starting diet, female and 
male mice were paired for mating.  Mated F0 mice were fed the diet throughout 
pregnancy and lactation. F1 mice were weaned at 28 days.  The F1 mice were then placed 
on a standard chow diet (PicoLab Laboratory Rodent Diet 5L0D, LabDiet, St. Louis, 
MO) or a 42% high-fat diet (HFD) (TD.88137).   
 
Glucose tolerance test (GTT) and insulin tolerance test (ITT) 
 Mice were transferred to clean cages with water for a 6-hour fast.  A 100mg/mL 
D-glucose solution was made in sterile -/- DPBS.  Mice were weighed before experiment 
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to calculate and record the volume of 10% glucose solution required (0.7g/kg body mass 
of glucose) for IP injections.  The volume of IP glucose injection (μl) =7 x body mass (g). 
The first drop of blood (approved, minimal tail snip) was discarded and a small drop of 
blood is placed on the test strip of an animal blood glucose meter (Abbott Alpha TRAK 2 
Blood Glucose Monitoring System) to record the fasting glucose level (t=0). Mice were 
restrained with an approved and trained method of scruffing. Appropriate amounts of 
glucose were injected into the peritoneum as calculated. The blood glucose levels were 
measured at 0 (before),15, 30, 60, 90, and 120 minutes following glucose injections and 
recorded. At the end of the experimental session, mice were placed in former cages.   
  
 Insulin tolerance tests were similarly carried out but with insulin solution 
(Humulin R, functional concentration: 1 unit/kg of body mass).  For smaller mice (mice 
on ND), a 1:1000 dilution of the insulin stock was used (100mU/mL), and for larger mice 
(mice on HFD), a 1:500 dilution of the insulin stock was used (200mU/mL).  If glucose 
measure falls below 25 mg/dL and/or the animal had significant activity/mobility 
decrease (responsiveness to a gentle finger prod), assay was immediately aborted, and the 
animal was injected with a dose of glucose.  GTT and ITT tests were carried out ≥7 days 
apart from one another to allow animals adequate recovery.   
 
Tissue extraction:  gWAT stromal vascular fraction 
Gonadal white adipose tissue (gWAT) is removed with minimal cuts, weighed, 
and placed into a sterile petri-dish containing ice cold dye-free Dulbecco’s Modified 
Eagle Medium (DMEM) containing 10% FBS (Gibco 21063-029) and 1% Penicillin 
Streptomycin (Gibco 15140-122).  Collagenase (Sigma Life Science, #C6885-1G) is 
prepared in DMEM buffer with a final 10mg/mL concentration.  gWAT fat pads were 
minced, gently passed through 100 μm filter, centrifuged (1500 RPM), and collagenase-
digested in an 37° C incubator for 45 min with rotation.  A second rinse-filter step 
follows.   ACK lysis (Lonza, #10-548E) is mixed into cell pellets and neutralized at 5 
minutes with ice cold PBS.  A third rinse-filter step occurs with cold PBS.  SVF cell 
fractions are resuspended in 1 mL of cold PBS and 10 μl is saved for trypan blue 
(Invitrogen) cell counting using the Cell Countess (Invitrogen). 
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Isolation of lymphocytes and cell counting 
Lymph nodes (inguinal, brachial, axillary, and superficial cervicals) were excised, 
collected through a 70 µm filter, and washed with ice cold buffer (5% fetal bovine serum 
(FBS), 0.4% EDTA in PBS) prior to centrifugation (3000 RPM, 5 min.) to form a cell 
pellet.  The supernatant was discarded and RBC depletion was performed with ACK 
(Lonza, #10-548E) and washed through a 70 µm filter to neutralize ACK.  After rinse and 
resuspension in cold sterile PBS buffer, 10 µl aliquots of each sample was used for a cell 
count using Trypan blue paired with an automated cell counter (Invitrogen Countess 
1754B).   
 
Flow cytometry stains 
SVF cells extracted from gWAT are washed and resuspended in sterile filtered 
FACs buffer (PBS, 0.5% BSA, 0.1% NaN3) and cells per sample are pooled together to 
form the control cells for Single Positive Controls (SPCs), Full-minus-one Controls 
(FMOs), and the negative cells.  Samples are blocked with anti-mouse CD16/CD32 
(eBioscienceaffymetrix #14-0161) for 1 hr on ice.  After rinsing, cells are incubated with 
anti-mouse CD45 (eBioscienceaffymetrix #48-0451), CD64 (BD Pharmingen 558455), 
CD11c (eBioscienceaffymetrix #47-0114), and CD206 (eBioscienceaffymetrix #17-
2061) for 1 hr on ice, in foil.  Cells were fixed with 2% paraformaldehyde (PFA) for 20 
min on ice prior to washing and storing in FACs buffer until analysis.  Samples were run 
on a LSRFortessa (University of Michigan Flow Cytometry Core) and analyzed on 
FlowJo version 10.0.0.1.  
 
mRNA isolation and RT-qPCR 
Total RNA was isolated from whole adipose tissue (gonadal / inguinal depots), 
homogenized in Qiazol lysis reagent (Qiagen, #1023537), and processed through a 
QIAshredder (Qiagen, #79656) prior to using the RNeasy Lipid Tissue Mini Kit (Qiagen, 
#1023539) in conjunction with a RNase-Free DNase (Qiagen, #79254) digestion step.  
Reverse transcription and cDNA amplification was performed with QuantiTect SYBR 
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Green RT-PCR Kit (Qiagen, #1054498) on a real-time R6-6006 Corbett Thermalcycler.  
All primers were obtained from IDT and specific primer sequences are listed (Table 1.1).   
 
Western blot 
Briefly, whole gWAT protein lysates were mixed with 4x Laemmli (Biorad #161-
0737), denatured, loaded at 40 μg per well into 15-well 4-20% gel casts (Biorad Mini-
PROTEAN TGX Precast Gels, #456-1096) and ran at 90V in a Tris/Glycine/SDS buffer.   
It was transferred to a PVDF membrane (BioradImmun-Blot, #1620177) in a 
Tris/Glycine/20% MeOH buffer at 100V.  Then, it is rinsed with TBS / 0.1% tween and 
blocked (Thermo Scientific Superblock T20, #37536) for 1 hr at RT on rotator.  Primary 
antibody (CHOP (anti-DDIT3 Abcam ab179823), P62 (Abcam ab9691526), or IgG (goat 
anti-mouse IgG-HRP Santa Cruz sc-2031), a-tubulin (Abcam ab18251)) is administered 
overnight in a 4°C cold room.  Blots were washed 3x 10 min with TBS / 0.1% tween 
prior to incubation with secondary antibody (in 5% non-fat milk powder in TBS/tween) 
for 30 min at RT on rotator.  Chemiluminescence is captured via Pierce ECL Western 
Blotting Substrate (Thermo Scientific, #32106) on Image Quant LAS 4000 (GE 
Healthcare) machine.  Densitometry is calculated with ImageJ software.   
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Results 
 
Figure 5-1 – Dietary and breeding protocol of methyl-donor supplementation diet study.   
F0 mice are placed on either a control or methyl-donor supplementation diet prior to and 
throughout breeding and lactation.  Post-weaning, F1 mice are placed on normal chow diet until 3 
months of age where they are either maintained on a normal chow diet (ND) or challenged with a 
42% high fat diet (HFD) for 16 weeks.  Following this, metabolic tests (glucose and insulin 
tolerance, and fasting insulin) commence and are spaced 1 week apart.  Mice are sacrificed 1 
week after at the age of 8-9 months old.   
We placed C57BL/6J mice on either a control or methyl-donor supplementation 
(MS) diet prior to and throughout breeding (Figure 5-1).  F1 mice generated from these 
two diet groups are then further separated into normal diet (ND) or a 42% high fat diet 
(HFD) challenge group three months post-weaning.  After 16 weeks of HFD challenge, 
the metabolic assays including glucose and insulin tolerance tests begin.  At ~8-9 months 
of age, F1 mice were sacrificed and the total body mass, gonadal white adipose tissue 
(gWAT) mass, and inguinal white adipose tissue (iWAT) mass were recorded (Figure 5-
2).  We found no differences between all adipose tissue masses recorded between the 
control and MS diet F1 mice from 3 sets of mice.  After 16 weeks of HFD, MS and 
control diet F1 mice were challenged with glucose and insulin (7 days later) to assess 
glucose (Figure 5-3) and insulin (Figure 5-4) tolerance.  Control and MS diet F1 mice of 
either gender do not have altered glucose tolerance test (GTT) nor insulin tolerance test 
(ITT) responses.  There is a modest decrease in blood glucose during a GTT in MS diet 
F1 female mice compared to controls, though this trend does not reach significance.   
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Figure 5-2 – Methyl-donor supplementation diet exposure does not alter F1 mice adiposity 
in response to diet-induced obesity challenge.   Whole body mass, gonadal white adipose tissue 
(gWAT), and inguinal white adipose tissue (iWAT) were collected.  For females, across 3 sets of 
mice, n=11-19 per group.  For males, n=16-25.  Open/white columns are F1 mice generated from 
control diet F0 and filled/black columns are F1 mice generated from MS diet F0.  All values 
plotted as mean ± SEM.   
 
 
 
Figure 5-3 – MS diet does not alter glucose tolerance test in F1 mice. (Top row) Female 
C57BL/6J mice were assessed with a glucose tolerance test and blood glucose was tracked over 
the course of two hours.  (Bottom row) Male C57BL/6J mice were assessed with a glucose 
tolerance test and blood glucose was tracked over the course of two hours.  Area under the curve 
(AUC) calculations are adjacent to corresponding graphs plotted as mean ± SEM.  For females, 
across 3 sets of mice, n=11-19 per group.  For males, n=16-25.  Open/white dots are F1 mice 
generated from control diet F0 and filled/black dots are F1 mice generated from MS diet F0.   
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Figure 5-4 – MS diet does not alter insulin tolerance test in F1 mice. (Top) Female C57BL/6J 
mice were assessed with an insulin tolerance test and blood glucose was tracked over the course 
of two hours.  (Bottom) Male C57BL/6J mice were assessed with an insulin tolerance test and 
blood glucose was tracked over the course of two hours.  Area under the curve calculations 
plotted as mean ± SEM.  For females, 3 sets of mice, n=11-19 per group.  For males, n=16-25.   
 
 
Figure 5-5 – Methyl-donor supplementation diet exposure does not alter F1 mice adipocyte 
size distribution. 8-9 month old C57BL6/J mice fed 42% HFD for 16 weeks were sacrificed and 
gWAT was fixed, sectioned and adipocytes were counted.  Adipocyte distribution was graphed 
and visualized on R (left).  H&E stained samples were used for counting and no sex difference 
was present. Representative images visualized on ImageJ (right).  For females, across 3 sets of 
mice, n=7-18 per group.  For males, n=15-19 per group.  Figures generated by Martin O’Brien. 
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Adipocyte sizing analysis indicates that MS diet F1 mice do not have altered 
adipocyte size distribution (Figure 5-5).  We collected stromal vascular fraction (SVF) 
cells from the gWAT to assess adipose tissue macrophage frequency by flow cytometry 
(Figure 5-6).  MS diet appears to not affect leukocyte (CD45+) frequency (Figure 5-6A).  
Similarly, adipose tissue macrophage subset (M1: CD45+CD64+CD11c+CD206- and M2: 
CD45+CD64+CD11c-CD206+) frequencies in F1 mice are unaffected (Figure 5-6A-B).  
We next measured mRNA of Il6, Tnfα, and Mcp1 in whole gWAT and also observe no 
significant differences between control and MS diet F1 mice (Figure 5-7A-B).  We found 
in male mice, MS diet led to higher AKT expression in F1 mice on normal diet compared 
to control diet (p<0.01), and we did not find any significant differences in AKT protein 
expression in female mice (Figure 5-8).   
 
 
 
 
Figure 5-6 – MS diet does not alter adipose tissue macrophage composition in F1 mice.  
Gonadal WAT stromal vascular fraction cells were extracted and stained for adipose tissue 
macrophages.  A) CD45+ and CD45- cells reported as a percentage of parent population.  B) 
Adipose tissue macrophages (CD45+CD64+) were reported in either CD11c+CD206- “M1” or 
CD11c-CD206+ “M2” as a percentage of parent population.  All values are graphed as mean ± 
SEM.  Flow cytometry data shown is 1 experiment with female mice n=4-6 per group and reflects 
trends in 3 other repeat-experiments with male and female mice.   
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Figure 5-7 – Expression of pro-inflammatory cyto- and chemo-kines in gWAT.  mRNA 
expression of Il6, Tnfα, and Mcp1 were assessed in gonadal WAT of A) female and B) male F1 
mice on either normal (ND) or high fat diet (HFD) with either an F0-diet background of control 
or methyl-donor supplementation (MS) diet.  For females, across 3 sets of mice, n=11-19 per 
group.  For males, n=16-25.  Open/white bars are F1 mice generated from control diet F0 and 
filled/black bars are F1 mice generated from MS diet F0.  All values reported as mean ± SEM.   
 
 
Figure 5-8 – MS diet male F1 mice on normal diet have increased p-Akt. Whole gonadal 
white adipose tissue protein lysates were used to measure phosphorylated-Akt in control and MS 
diet F1 mice.  For females, across 3 sets of mice, n=7-18 per group.  For males, n=15-19 per 
group.  Open/white bars are F1 mice generated from control diet F0 and filled/black bars are F1 
mice generated from MS diet F0.  All values reported as mean ± SEM.   
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Discussion 
In the classic agouti viable yellow (Avy) mouse, the methyl-donor supplementation 
(MS) diet protects F1 mice from obesity and tumor development.  In another agouti 
mouse study, it was reported that the MS diet can protect from bisphenol A (BPA)-
induced hypomethylation in F1 mice.  This study is considered an important 
demonstration of an environmental-stress biosensor mouse model21, but it should be 
noted that a different study could not repeat these findings26.  We have previously 
reported that the MS diet in C57BL/6J mice are born smaller and maintain smaller bodies 
into adulthood33.  In this study, we tested if the MS diet can protect F1 mice from diet-
induced obesity (DIO) and found that the MS diet does not protect F1 mice from DIO nor 
obesity-associated metabolic function and adipose tissue inflammation.   
 
We observe that the MS diet F1 mice of both sexes had similar body and fat pad 
(gonadal and inguinal) masses to that of control diet F1 mice.  Glucose and insulin 
tolerance tests indicate that both diet F1 mice were similarly affected by the 42% high fat 
diet.  There was some indication that the MS diet could be protective in female mice, but 
the modest decrease of glucose tolerance response in MS diet F1 mice fed the normal diet 
(ND) was absent in MS diet F1 mice fed the 42% high fat diet (HFD).  Our GTT and ITT 
experiments indicate that the metabolic function between MS and control diet F1 mice 
were similar under both ND and HFD feeding conditions.  We analyzed the adipose 
tissue and found that the macrophage subset proportions were also similar between the 
two pre- and peri-natal diet F1 mice.  Interestingly, we saw a moderate increase in AKT 
protein expression in MS diet male mice fed the ND, but without changes in other 
measured parameters, we are unable to make a conclusive interpretation of this 
difference.  
 
Previous studies have shown that a similar methyl-donor diet (with an addition of 
genistein and lower methionine) can be protective in the context of gestational diabetes or 
HFD intake during pregnancy243,244.  One study showed some evidence that C57BL/6J 
pregnant dams fed a 60% HFD during gestation leads to obesity and obesity-associated 
adverse effects in F1 mice that could be mildly reversed if the HFD had methyl-donor 
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supplementation243.  They also report that a control diet infused with MS diet led to 
smaller C57BL/6J pups being born243, similar to what we have reported33.  However, the 
study did not yield many useful conclusions as the data analyses seemed inappropriately 
executed (they compared F1 mice from dams fed control + MS to F1 mice from dams fed 
HFD + MS rendering it impossible to interpret if MS diet protects F1 from HFD intake 
during gestation—but they claim that it does).  A subsequent study performed by another 
group aimed to repeat and clarify these experiments using an identical MS diet as the first 
study, but they also elected to use a 45% HFD instead244.  Their rationale behind the HFD 
switch was primarily because 60% HFD is abnormally high and may be testing an 
extreme form of overnutrition.  This study reported highly significant and beneficial 
differences between F1 mice derived from HFD dams and the F1 mice from HFD + MS 
diet dams.  F1 mice from the latter are born with similar body masses but do not gain 
weight like their HFD F1 mice and have improved metabolic parameters in comparison 
(e.g. increased pparγ, leptin, adiponectin, fas expression, decreased plasma glucose, 
HDL, FFA, and increased plasma insulin).   
 
In this current study, we asked a different question by challenging MS diet F1 
mice (instead of the dams) with HFD consumption.  In the agouti viable yellow (Avy) 
mice, the MS diet strongly prevents a genetically-predisposed type of obesity18, and this 
elicited the question of how effective this would be in a non-agouti model.  Our data 
suggests that the MS diet’s protective effect of obesity in F1 mice are limited to the 
agouti mouse model, where the agouti gene is highly sensitized to methylation18,21,23–25.   
Furthermore, methylation directly affects the primary culprit (ectopic agouti expression).  
It is therefore reasonable that using the MS diet in a wild-type, common laboratory 
mouse strain with no unique retrotransposon insertion in its agouti gene promoter yielded 
no beneficial protection.  It remains possible that a different mouse strain from agouti or 
C57BL/6J could also have different responses to the MS diet.  Agouti mice are known for 
their exemplary modeling of diet, epigenetics, and later-life obesity/tumors, but it seems 
this model, based on our data, could be an idiosyncratic feature of the agouti mice.   
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Table 3 – Sequences for RT-PCR primers used in this chapter 
 
 
Gene of 
Interest Forward 5’  3’ Reverse 5’  3’ 
Il6 CTTCCATCCAGTTGCCTTCT CTCCGACTTGTGAAGTGGTATAG 
Tnf𝛼𝛼 TTGTCTACTCCCAGGTTCTCT GAGGTTGACTTTCTCCTGGTATG 
Mcp1 CTCACCTGCTGCTACTCATTC ACTACAGCTTCTTTGGGACAC 
Gapdh AACAGCAACTCCCACTCTTC CCTGTTGCTGTAGCCGTATT 
94 
 
Chapter 6 – Conclusions and Future Directions 
 
Final Notes (Chapter 2) 
In Chapter 2, early-life pharmaceutical lifespan interventions were administered 
to HET3 mice, and we measured adipose tissue biology parameters at the 22-month time 
point to determine if these drugs prevented or mitigated age-associated effects in the 
adipose tissue.  As discussed in Chapter 2, the high variation and range in old control data 
demonstrates that aging experiments and working with a heterogeneous mouse strain may 
require more attention to experimental design for optimization.  In these final notes, I 
wish to highlight thoughts that our lab and I have discussed that are useful to improve 
future work related to (aging) adipose tissue biology and its relation to lifespan.   
In Chapter 2, we noted in the discussion that the old control HET3 mice had a 
large variation.  The separation of the old control mice into distinct groups is not limited 
to the use of heterogeneous mice.  Our lab has previously noted within homogenous, in-
bred strains of mice, old mice similarly separate, with age, into different groups.  In 
murine studies where a measured variable in homogenous and young mice have a small 
standard error of mean, the analysis is straightforward—the average of the young control 
mice is representative of the cohort.  However, in this case (Chapter 2) where the variable 
(aging biomarker) is affected by age and heterogeneous animals are used, the standard 
error of mean is large.  There could either be a wide-range of values or clustering of data 
groups.  In either of these scenarios, the analysis is complicated in a few ways.  Variation 
in an aging variable tested in HET3 mice or another heterogeneous mouse strain may 
signify that this is a strain-specific aging biomarker (or idiosyncrasy) and therefore is 
different (or absent) in heterogeneous mice.   
However, the variation of an aging biomarker could also represent a natural 
phenomenon associated with differential aging outcomes and may be cumulative of 
genetic predisposition or unknown environmental-epigenetic interactions throughout their 
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lives.  Future work will benefit from anticipating these outcomes and would justify using 
larger control groups.  If the data and numbers allow (is sufficient for separate analysis), 
it would be useful to consider separating the controls into at least 2 groups to analyze and 
discuss.  What is lacking is a clearer understanding behind the separation of these control 
points.  I believe that setting up operational definitions (where we can distinguish old 
mice based on criteria for categorization) for these groups could both prevent difficult 
interpretation of data and better model the differential aging outcomes we see in humans 
in these heterogeneous mouse models.   
The 22-month time point we selected for the adipose tissue biology evaluation 
posed a few lessons.  An important phenomenon we had not taken into account prior to 
these experiments was that at the 22-month time point, HET3 male mice in particular 
begin to undergo age-associated body mass decline.   Old-age adipose tissue 
inflammation is typically associated and studied in conjunction with age-related 
adiposity.  However, the more advanced stages of aging preceding death can also be 
accompanied by body mass decline.  Based on previous studies143,145,169 that recorded 
HET3 mice body masses at several additional time points (at 6-, 12-, 18-, 20-) during 
lifespan measurements, we observe that males have had substantial body mass reduction 
between 18 and 22 months of age.  Female HET3 mice also appear to obtain peak body 
mass around 18 months of age, but compared to their male counterparts, it appears they 
lose smaller quantities of body mass and/or have delayed body weight decline.  Given 
that female HET3 mice live longer than males, as previously discussed in Chapter 2, the 
decline in body mass we observed in the males is a later-stage of aging than females.  
Therefore, the 22-month time point may be beyond the stage at which it is most 
appropriate to study old-age adipose tissue inflammation, at least in HET3 mice.  This, 
imaginably, could be important for other strains of mice where the time and duration of 
the stages of aging and body mass fluctuations are different, but they could similarly be 
present.   
A limitation for interpretation of our senescent-marker expression in inguinal 
white adipose tissue (iWAT) is the data on p16 expression. There is a recent report that 
found p16-positive macrophages surround senescent cells in an ex vivo synthetic model 
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with glass beads245,246.  This study’s data suggest that p16-positive ‘senescent cells’ 
extracted from various tissues may be a mixture of p16-positive senesced cells along with 
the recruited p16-positive macrophages that may be attempting to clear the senescent 
cells.  This indicates that it is possible that studies that have reported the inflammatory 
nature of the so-called senescence-associated secretory phenotype (SASP) is 
documenting macrophage inflammation and not senescent cells’ inflammation.  Another 
possibility is that macrophages are prone to senescence in old age, and therefore p16 may 
be marking primarily senescence of macrophages which are already equipped to secrete 
pro-inflammatory mediators.     
The significant increase in M1 macrophages in Rapa-treated HET3 mice, as 
discussed is also interesting in that it was associated to a previous study showing that 
they have compromised glucose tolerance but intact insulin tolerance142,143.  An 
interesting future direction could be to assess the chemo-/cytokine profile of these 
adipose tissue macrophages and determine if these macrophages are enhanced regionally 
or systemically.  For future work involving aging adipose tissue biology and ITP drugs, it 
may be important to also assess other immune cells that have been attributed as metabolic 
health influencers such as regulatory T cells (Tregs) in the fat pad.  The work presented 
in Chapter 2 primarily showed that 1 of 3 ITP drugs we tested (Rapa) could be affecting 
adipose tissue inflammation as a means of lifespan extension.  An important question 
would be what function these M1 macrophages serve in Rapa-treatment and whether they 
are a negative, neutral, or positive contributor to the lifespan extension benefits in HET3 
mice.   
 
Final Notes (Chapter 3 & 4) 
 In Chapter 3, a spontaneous outbreak of C. difficile in our mouse colony was 
presented and in Chapter 4, we used the outbreak strain (‘16N203’) derived from Chapter 
3 to test our hypothesis that the methyl-donor supplement (MS) diet leads to a microbiota 
that loses colonization resistance against C. difficile infection (CDI).  In these final notes, 
I discuss the challenges we faced during the outbreak investigation and the subsequent 
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study that tried to recapitulate the observations we had during the outbreak under 
experimental conditions.   
 We observed during the outbreak that MS diet F1 mice had higher total mortality 
than control mice.  Three of the biggest variables we were unable to include or grasp in 
our subsequent experimental design was 1) barrier from which animals were ordered, 2) 
uncontrolled outbreak conditions (spores, continuous husbandry handling, etc.) and 3) 
age of animals.  These discussions will also be broadly useful to reproducibility issues 
bound to model-based biomedical research in mice. 
Within the data in Chapter 4, we discussed the possible conditions that could 
explain why the F1 diet mice did not lose colonization resistance with the MS diet alone.  
One of our primary concerns was that the Jackson Laboratory barrier from which the 
mice were ordered differed between the ‘outbreak’ mice and the batch of mice we raised 
in the new mouse colony.  Surmounting literature and studies indicate that even a 
horizontal transfer between mouse rooms in the same institution could result in different 
microbiota247.  Recently, studies on vendor and vendor-barrier effects on microbiota were 
shown to be significantly different228,248.  In the future, even if the same barrier from 
which the outbreak mice were sourced was used for experiments, the microbiota could 
have already shifted.  However, this emphasizes that barriers are crucial for 
reproducibility and consistency in microbiota studies—though it could be argued that any 
biological animal model system would be plagued by these variables as well.   
Our second set of concerns for the outbreak investigation and the subsequent use 
of the outbreak strain in an experimental model was the number of conditions we cannot 
account for that occurred in the outbreak.  In our experimental testing of 16N203-CDI 
(Chapter 4), we used a standard quantity of spores (104) to infect the animals, and we 
retain control over how many exposures this will be.  However, during the outbreak, the 
spore quantity was unknown, and the lengthy outbreak period (over 8 months) ensures 
that multiple exposures of spores and cycles of re-infection may have affected the acuity 
of the outbreak.  Thinking back to the experimental data we collected in Chapter 4, we 
suspect that these unaccounted conditions may explain why a microbiota shift in 
experimental conditions did not lead to colonization resistance loss.  Along this point, a 
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microbiota shift in the context of multiple re-infection and varying quantities of spores in 
the mouse colony outbreak could be how the F1 diet mice suffered higher mortality than 
controls without antibiotics.   
In the outbreak (Chapter 3), mice of all ages were present in the colony.  Many of 
our older mice (13-16 months old) were lost in comparison to the younger mice, but this 
could not be a reportable observation given the associations drawn would be based on 
numerous age groups.  However, C57BL/6J mice typically do not die from age-related 
causes in their middle ages.  Therefore, it is rational to consider that in the experimental-
infection (Chapter 4), using 3-4-months old adult F1 mice may be another important 
limitation-factor.  The age-associated risk of CDI is known and one of beliefs is that there 
is age-associated decline in microbial diversity in the gut.  Knowledge on age-related 
shifts in gut microbiota is still in its infancy249, and this factor, in conjunction with MS 
diet, may have also synergistically enabled an advantageous environment for 16N203 
CDI during the outbreak that could not be recapitulated in our younger-infection model. 
In Chapter 4, I also test, alternative to the microbiota, if the MS diet led to 
different host immune responses that could have contributed to the increased mortality in 
MS diet F1 mice in the outbreak.  However, the use of a dose of clindamycin to 
encourage CDI manifestation in the study also led to flattening of the microbiota in both 
control and MS diet F1 mice.  This prevents a true assessment of my original question.  
Furthermore, an important lesson and limitation from isolating mesenteric lymph nodes 
and Peyer’s patches in mice infected with CDI is that the selected immunological time 
point at 48-hours post-colonization was difficult.  At 48 hours, mice were extremely sick, 
and the isolated immune cells may be similarly dysfunction and yield misleading results.  
For example, we did not observe any difference in T cell numbers nor subset differences 
between mock and C. difficile-infected animals.  During C. difficile colitis, extensive 
damage of the gastrointestinal tissues has already occurred (as noted in histopathology) 
and the immune cells isolated at this time point in the mesenteric LN and PP likely do not 
accurately represent a host immune response to CDI.  Instead, it may reflect an acute, 
pre-mortem phase.  Discussions with other colleagues who work on gut inflammation 
have confirmed these points of concern.  The better time points may be at 12 or 24 hours 
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(depending on strain and dosages), but the location of immunological assessment should 
also include the lamina propria to measure mucosal-regional responses.    
Final Notes (Chapter 5) 
In Chapter 5, the MS diet used in a C57BL/6J F0 mice do not generate F1 mice 
that are protected from diet-induced obesity (DIO) as we had hypothesized and have seen 
in previous reports on the agouti mice.  Based on the data presented in this dissertation 
and the HFD consumption-during-gestation studies in literature243,244, the MS diet may be 
uniquely protective in the agouti mouse model or as a counterbalance to HFD 
consumption during murine gestation.  The limitation to these conclusions is that the 
gestational studies were done with a similar but different MS diet where there was an 
addition of genistein and a 37.5% reduction in methionine supplementation levels per kg 
of diet243,244.  In our MS diet, which is modeled after the agouti mice obesity study, we 
use 12g/kg methionine whereas the gestational studies used 7.5g/kg methionine and an 
additional 0.3g/kg genistein.   
Another important lesson from Chapter 5 is that we used F1 mice from different 
litters prior to realizing that the metabolic outcomes in each litter may vary.  We observe 
variation between the GTT and ITT outcomes between each litter in both MS and control 
diet mice. When the data is pooled across the 3 litters, the data was flattened.  Due to the 
limitation of time and loss of time from the outbreak that occurred in our mouse colony, 
we decided against repeating the experiment in another set of mice and looking at 
whether litter truly affected metabolic outcomes.  However, in the future, these 
observations (though unconfirmed at this point) may be useful for explaining the 
difficulty behind repeating biological models, in addition to the microbiota obstacles 
discussed in Chapter 3’s and 4’s final notes.    
The MS diet study originated from our observation that MS diet F1 mice are born 
smaller and maintain smaller body masses into adulthood at various ages33.  The smaller 
body mass does not appear to affect lifespan (unpublished) and appear to diminish with 
age, but on average, it was still a significant percent of body mass difference (~5-15%).  I 
also noted that MS diet F1 mice either had smaller numbers per litter born or fewer F1 
newborn pups survive to weaning stages.  This may be due to smaller F1 may be deemed 
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unfit by parents and killed.  We attempted to carefully count newborns immediately and 
found that MS diet F1 mice seem to be born in similar numbers as control diet F1 mice.   
Therefore, another possibility is MS diet F1 mice have decreased viability during early 
childhood, but without further and more exact experiments, this question remains 
unanswered.  Necessary improvements to the MS diet and metabolic-outcomes related 
studies would be to clearly document its effect on litter viability and sizes.  Addressing 
these variables could better inform the applicability and optimal dosages of the MS diet.  
The methyl-donor composition and proportions may be appropriate for the agouti mice 
model but may be too high for C57BL/6J mice—given that hypomethylation at the agouti 
promoter leads to obesity and tumors, but in C57BL/6J mice, the level of methyl-donors 
deficiency could be different.   
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Summary 
Chapters 2-5 are of separate questions but converge on the note that they explore 
the effect of either a diet or drug early in life and its impact on later life disease.  In 
Chapter 2, the project tested the effects of 3 Interventions Testing Program (ITP) drugs, 
acarbose (ACA), 17α-estradiol (17aE2), and rapamycin (Rapa), on adipose tissue 
inflammation.  We found that ACA and 17aE2 do not significantly affect any aspect of 
adipose tissue biology we tested while Rapa significantly increased pro-inflammatory 
adipose tissue macrophages.  The subsequent chapters (3-5) all stem from the use of the 
methyl-donor supplementation (MS) diet mouse model.  While investigating a 
spontaneous C. difficile outbreak (Chapter 3), we observed higher mortality in MS diet 
F1 mice during the outbreak, and after successful identification and isolation of the 
outbreak strain ‘16N203’ we attempted to test our observation under experimental 
conditions.  We infected MS diet F1 mice with the 16N203 C. difficile.  Interestingly, we 
found that the MS diet significantly alters the F1 microbiota, and these changes alone did 
not allow for C. difficile colonization and infection.  In Chapter 5, I present data from the 
original thesis project that explored whether MS diet protects F1 mice from diet-induced 
obesity and aspects of the DIO-associated metabolic syndrome.  Important to note, the 
original project challenges F1 mice at 1 month of age (nearly immediately after weaning).  
However, due to the interruption of the outbreak, this time point was shifted to 3 months 
of age in all three sets of mice reported in Chapter 5.  We find that the MS diet does not 
alter DIO nor metabolic responses in F1 C57BL/6J mice which suggests that the 
protective effects of the MS diet may be limited to preventing the adverse effects of 
maternal HFD intake during gestational phase of the fetus as previously reported by 
others243,244 and/or unique to the agouti viable yellow (Avy) mouse model.   
The data in this dissertation supports and emphasizes the importance of diet, 
adipose tissue biology, and inflammation in the intersection of early-life diet and later-
life disease.  Moreover, the dissertation demonstrates that early interventions can affect 
an organism’s disease susceptibility and health outcomes later in its own life (Chapter 2) 
as well as in the subsequent generation (Chapter 3-5).  
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